TWI760194B - A drinking water that improves sleep quality - Google Patents

A drinking water that improves sleep quality Download PDF

Info

Publication number
TWI760194B
TWI760194B TW110114227A TW110114227A TWI760194B TW I760194 B TWI760194 B TW I760194B TW 110114227 A TW110114227 A TW 110114227A TW 110114227 A TW110114227 A TW 110114227A TW I760194 B TWI760194 B TW I760194B
Authority
TW
Taiwan
Prior art keywords
lithium
drinking water
sleep
sample
calcium
Prior art date
Application number
TW110114227A
Other languages
Chinese (zh)
Other versions
TW202142123A (en
Inventor
章霞
沈妍
李棟
Original Assignee
大陸商浙江養生堂天然藥物研究所有限公司
大陸商農夫山泉股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商浙江養生堂天然藥物研究所有限公司, 大陸商農夫山泉股份有限公司 filed Critical 大陸商浙江養生堂天然藥物研究所有限公司
Publication of TW202142123A publication Critical patent/TW202142123A/en
Application granted granted Critical
Publication of TWI760194B publication Critical patent/TWI760194B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/02—Non-contaminated water, e.g. for industrial water supply
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/02—Non-contaminated water, e.g. for industrial water supply
    • C02F2103/026—Treating water for medical or cosmetic purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hydrology & Water Resources (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental & Geological Engineering (AREA)
  • Water Supply & Treatment (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申請涉及食品領域，具體涉及一種改善睡眠品質的飲用水。特別地，本申請涉及含有特定含量和種類的礦物質的飲用水用於改善睡眠品質或緩解睡眠障礙的用途。本申請還涉及一種改善睡眠品質或緩解睡眠障礙的方法，包括使有此需要的受試者飲用該含有特定含量和種類的礦物質的飲用水。The present application relates to the field of food, in particular to a drinking water for improving sleep quality. In particular, the present application relates to the use of drinking water containing certain contents and types of minerals for improving sleep quality or alleviating sleep disorders. The present application also relates to a method for improving sleep quality or alleviating sleep disorders, comprising causing a subject in need thereof to drink the drinking water containing minerals of a specific content and type.

Description

一種改善睡眠品質的飲用水A drinking water that improves sleep quality

本發明涉及一種飲用水，具體涉及該飲用水在改善睡眠品質中的用途The invention relates to drinking water, in particular to the use of the drinking water in improving sleep quality

人的一生有三分之一的時間在睡眠中度過，睡眠對人體具有極為重要的生理意義。現代醫學研究表明在睡眠狀態時人體表現肌肉放鬆、神經反射減弱、體溫下降、心跳減慢、血壓輕度下降，新陳代謝的速度減慢，胃腸道蠕動明顯減弱等變化，這一系列生理現象變化，可促進機體的體能與智力的恢復，緩解緊張情緒、鞏固記憶、增強免疫、延緩衰老，因此睡眠是生命健康不可缺少的重要組成部分，是人類生命所必需。One third of a person's life is spent in sleep, and sleep is of great physiological significance to the human body. Modern medical research has shown that during sleep, the human body exhibits muscle relaxation, weakened nerve reflexes, decreased body temperature, slowed heartbeat, mildly decreased blood pressure, slowed metabolism, and significantly weakened gastrointestinal motility. This series of physiological phenomena changes, It can promote the recovery of the body's physical energy and intelligence, relieve tension, consolidate memory, enhance immunity, and delay aging. Therefore, sleep is an indispensable and important part of life and health and is necessary for human life.

然而，隨著現代生活節奏的加快，越來越多的人受到睡眠不足甚至失眠的困擾。據不完全統計，全球有近25%的人受到睡眠不足或睡眠品質差的困擾。經調查顯示：近年來，我國睡眠障礙患者約有4.5億，其中2億以上生活在城市，以婦女和中老年人居多，嚴重影響了人們的工作、學習和生活品質。許多業內人士認為，隨著現在人們生活壓力的不斷增大，睡眠將會困擾更多的人。However, with the accelerated pace of modern life, more and more people suffer from lack of sleep or even insomnia. According to incomplete statistics, nearly 25% of people in the world suffer from insufficient sleep or poor sleep quality. According to the survey, in recent years, there are about 450 million patients with sleep disorders in my country, of which more than 200 million live in cities, most of them are women and middle-aged and elderly people, which seriously affects people's work, study and quality of life. Many people in the industry believe that with the increasing pressure of people's lives, sleep will trouble more people.

目前，用於失眠治療的藥物主要有***劑、褪黑素等。當睡眠障礙干擾人的正常活動時，間歇性使用***劑可能是有用的。通常可獲得的現代***物都是非處方藥劑並且是較常用的市售藥品之一。然而，許多目前可獲得的***丸，特別是***和鎮靜藥不應該長期服用。連續長期使用可能導致人對該藥物建立耐受性，另外有可能惡化原來的睡眠障礙，容易成癮，並且停止使用時引起停藥症狀。另外，目前可獲得的***劑的常見副作用可以包括抑制肌肉協調系統、中樞神經系統和一般機能能力，例如拖著腳步走；震顫，無法靜止不動或心律不整。褪黑素是近年來用於改善睡眠的主要原料，此類產品主要是藉由補充人體可能缺乏的一種自身所分泌的激素達到改善睡眠的作用。但有科學研究表明，褪黑素改善睡眠（倒時差）功效尚不確切，長期或高劑量服用褪黑素可能對人體產生危害，如明顯抑制人體生殖系統功能。At present, the drugs used for the treatment of insomnia mainly include hypnotics and melatonin. Intermittent use of hypnotics may be useful when sleep disturbances interfere with a person's normal activities. Commonly available modern sleeping pills are over-the-counter and one of the more commonly available commercially available drugs. However, many currently available sleeping pills, especially sleeping pills and sedatives, should not be taken long-term. Continued long-term use may cause a person to build up tolerance to the drug, additionally may worsen the original sleep disturbance, become addictive, and cause withdrawal symptoms upon discontinuation. Additionally, common side effects of currently available hypnotics can include inhibition of the muscle coordination system, central nervous system, and general functional abilities, such as shuffling; tremors, inability to stand still, or cardiac arrhythmias. Melatonin is the main raw material used to improve sleep in recent years. Such products mainly improve sleep by supplementing a hormone secreted by the human body that may be lacking. However, some scientific studies have shown that the efficacy of melatonin in improving sleep (jet lag) is not yet accurate. Long-term or high-dose use of melatonin may cause harm to the human body, such as significantly inhibiting the function of the human reproductive system.

睡眠對於人健康的生活方式是至關重要的，人們現在需要提供副作用較小且不致癮的用於改善睡眠品質的方法。目前，國內外已有多款用於改善睡眠的藥物和保健食品，但還沒有任何具有改善睡眠功能的飲用水產品。Sleep is essential to a healthy lifestyle, and there is now a need to provide methods for improving sleep quality that have fewer side effects and are not addictive. At present, there are many medicines and health foods for improving sleep at home and abroad, but there is no drinking water product with the function of improving sleep.

發明人經過創造性的勞動，發現含有特定含量和種類的礦物質的飲用水可以改善睡眠品質，從而提供了以下發明。After creative work, the inventors found that drinking water containing specific content and types of minerals can improve sleep quality, thus providing the following invention.

在一個方面，本申請提供了飲用水用於改善睡眠品質或緩解睡眠障礙的用途，該飲用水含有0.1~5mg/L鋰和0.1~200mg/L鈣，或含有0.1~5mg/L鋰和0.1~100mg/L鎂，該用途不用於診斷或治療目的。In one aspect, the present application provides the use of drinking water for improving sleep quality or alleviating sleep disorders, the drinking water contains 0.1-5 mg/L lithium and 0.1-200 mg/L calcium, or 0.1-5 mg/L lithium and 0.1 ~100mg/L magnesium, this use is not for diagnostic or therapeutic purposes.

在某些實施方案中，該飲用水中的鋰、鈣和鎂分別以Li+ 、Ca2+ 、Mg2+ 的形式存在。In certain embodiments, the lithium, calcium, and magnesium in the drinking water are present in the form of Li + , Ca 2+ , Mg 2+ , respectively.

在某些實施方案中，該飲用水中的鋰含量為0.1~0.2mg/L、0.2~0.5mg/L、0.5~1mg/L、1~2mg/L、2~3mg/L、3~4mg/L或4~5mg/L。In certain embodiments, the lithium content in the drinking water is 0.1-0.2 mg/L, 0.2-0.5 mg/L, 0.5-1 mg/L, 1-2 mg/L, 2-3 mg/L, 3-4 mg /L or 4~5mg/L.

在某些實施方案中，該飲用水中的鈣含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~60mg/L、60~80mg/L、80~100mg/L、100~120mg/L、120~140mg/L、140~160mg/L、160~180mg/L或180~200mg/L。In certain embodiments, the calcium content in the drinking water is 0.1-1 mg/L, 1-10 mg/L, 10-20 mg/L, 20-40 mg/L, 40-60 mg/L, 60-80 mg/L , 80~100mg/L, 100~120mg/L, 120~140mg/L, 140~160mg/L, 160~180mg/L or 180~200mg/L.

在某些實施方案中，該飲用水中的鎂含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~50mg/L、50~60mg/L、60~80mg/L或80~100mg/L。In certain embodiments, the magnesium content in the drinking water is 0.1-1 mg/L, 1-10 mg/L, 10-20 mg/L, 20-40 mg/L, 40-50 mg/L, 50-60 mg/L , 60~80mg/L or 80~100mg/L.

在某些實施方案中，該飲用水還包含以下元素中的一種或多種：鍶、鉀、鈉。In certain embodiments, the drinking water further comprises one or more of the following elements: strontium, potassium, sodium.

在某些實施方案中，該飲用水中的鍶、鉀、鈉分別以Sr2+ 、K+ 、Na+ 的形式存在。In certain embodiments, strontium, potassium, and sodium in the drinking water are present in the form of Sr 2+ , K + , Na + , respectively.

在某些實施方案中，該飲用水中的鍶含量為0.4~1.5mg/L，例如0.4~0.6mg/L、0.6~0.9mg/L、0.9~1.2mg/L或1.2~1.5mg/L。In certain embodiments, the strontium content in the drinking water is 0.4-1.5 mg/L, such as 0.4-0.6 mg/L, 0.6-0.9 mg/L, 0.9-1.2 mg/L, or 1.2-1.5 mg/L .

在某些實施方案中，該飲用水中的鉀含量為0.8~3mg/L，例如0.8~1mg/L、1~1.5mg/L、1.5~2mg/L或2~3mg/L。In certain embodiments, the potassium content in the drinking water is 0.8-3 mg/L, such as 0.8-1 mg/L, 1-1.5 mg/L, 1.5-2 mg/L, or 2-3 mg/L.

在某些實施方案中，該飲用水中的鈉含量為50~160mg/L，例如50~80mg/L、80~100mg/L、100~130mg/L或130~160mg/L。In certain embodiments, the sodium content in the drinking water is 50-160 mg/L, such as 50-80 mg/L, 80-100 mg/L, 100-130 mg/L, or 130-160 mg/L.

在某些實施方案中，該飲用水還包含偏矽酸。In certain embodiments, the drinking water further comprises metasilicic acid.

在某些實施方案中，該飲用水中的偏矽酸含量為6~20mg/L，例如6~8mg/L、8~9.5mg/L、9.5~12mg/L、12~15mg/L或15~20mg/L。In certain embodiments, the metasilicic acid content in the drinking water is 6-20 mg/L, such as 6-8 mg/L, 8-9.5 mg/L, 9.5-12 mg/L, 12-15 mg/L or 15 ~20mg/L.

在某些實施方案中，該飲用水還包含碳酸根和氯離子。In certain embodiments, the drinking water further comprises carbonate and chloride ions.

在某些實施方案中，該飲用水含有0.2~0.5mg/L鋰和4~20mg/L鈣，以及任選的鍶、鉀、鈉和/或偏矽酸。In certain embodiments, the drinking water contains 0.2-0.5 mg/L lithium and 4-20 mg/L calcium, and optionally strontium, potassium, sodium and/or metasilicic acid.

在某些實施方案中，該飲用水含有0.2~0.5mg/L鋰和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。In certain embodiments, the drinking water contains 0.2-0.5 mg/L lithium and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid.

在某些實施方案中，該飲用水含有0.2~0.5mg/L鋰、4~20mg/L鈣以及1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。In certain embodiments, the drinking water contains 0.2-0.5 mg/L lithium, 4-20 mg/L calcium, and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium, and/or metasilicic acid.

在某些實施方案中，該飲用水含有0.2~0.5mg/L鋰，0.4~1.5mg/L鍶，4~20mg/L鈣，1~6mg/L鎂，6~20mg/L偏矽酸，0.8~3mg/L鉀，以及50~160mg/L鈉。In certain embodiments, the drinking water contains 0.2-0.5 mg/L lithium, 0.4-1.5 mg/L strontium, 4-20 mg/L calcium, 1-6 mg/L magnesium, 6-20 mg/L metasilicic acid, 0.8~3mg/L potassium, and 50~160mg/L sodium.

在某些實施方案中，該飲用水是礦泉水或礦物質水。In certain embodiments, the drinking water is mineral water or mineral water.

在某些實施方案中，該飲用水被包裝於容器（例如玻璃瓶、塑膠瓶、盒、罐或桶）中。In certain embodiments, the drinking water is packaged in containers (eg, glass bottles, plastic bottles, boxes, jars, or buckets).

在一個方面，本申請提供了一種改善睡眠品質或緩解睡眠障礙的方法，該方法包括使有此需要的受試者飲用如上任一項定義的飲用水，該方法不用於診斷或治療目的。In one aspect, the application provides a method of improving sleep quality or alleviating sleep disturbances, the method comprising causing a subject in need thereof to drink drinking water as defined in any of the above, the method not being used for diagnostic or therapeutic purposes.

在某些實施方案中，該方法包括使有此需要的受試者每日飲用至少24mL該飲用水，例如24~40mL、40~60mL、60~80mL、80~100mL、100~120mL、120~150mL、150~200mL、200~300mL、300~400mL、400~500mL、500~600mL、600~700mL或700mL以上該飲用水。在某些實施方案中，該方法包括使有此需要的受試者按照上述量飲用該飲用水至少1天，例如1~7天、7~10天或10~30天。In certain embodiments, the method comprises causing a subject in need thereof to drink at least 24 mL of the drinking water per day, such as 24-40 mL, 40-60 mL, 60-80 mL, 80-100 mL, 100-120 mL, 120-120 mL 150mL, 150~200mL, 200~300mL, 300~400mL, 400~500mL, 500~600mL, 600~700mL or more than 700mL of the drinking water. In certain embodiments, the method comprises causing a subject in need thereof to drink the drinking water in the above amount for at least 1 day, eg, 1-7 days, 7-10 days, or 10-30 days.

在一個方面，本申請提供了含有鋰、鈣、鎂的水在製備用於改善睡眠品質或緩解睡眠障礙的食品或藥物中的用途，該水中，鋰的含量為0.1~5mg/L且鈣的含量為0.1~200mg/L，或鋰的含量為0.1~5mg/L且鎂的含量為0.1~100mg/L。In one aspect, the present application provides the use of water containing lithium, calcium and magnesium in the preparation of food or medicine for improving sleep quality or relieving sleep disorders, the water having a lithium content of 0.1-5 mg/L and a calcium content of 0.1-5 mg/L. The content is 0.1 to 200 mg/L, or the content of lithium is 0.1 to 5 mg/L and the content of magnesium is 0.1 to 100 mg/L.

在某些實施方案中，該食品為飲料。In certain embodiments, the food product is a beverage.

在某些實施方案中，該食品為飲用水，例如礦泉水或礦物質水。In certain embodiments, the food product is drinking water, such as mineral water or mineral water.

在某些實施方案中，該水中的鋰、鈣和鎂分別以Li+ 、Ca2+ 、Mg2+ 的形式存在。In certain embodiments, the lithium, calcium, and magnesium in the water are present as Li + , Ca 2+ , Mg 2+ , respectively.

在某些實施方案中，該水中的鋰含量為0.1~0.2mg/L、0.2~0.5mg/L、0.5~1mg/L、1~2mg/L、2~3mg/L、3~4mg/L或4~5mg/L。In certain embodiments, the lithium content in the water is 0.1-0.2 mg/L, 0.2-0.5 mg/L, 0.5-1 mg/L, 1-2 mg/L, 2-3 mg/L, 3-4 mg/L or 4~5mg/L.

在某些實施方案中，該水中的鈣含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~60mg/L、60~80mg/L、80~100mg/L、100~120mg/L、120~140mg/L、140~160mg/L、160~180mg/L或180~200mg/L。In certain embodiments, the calcium content in the water is 0.1-1 mg/L, 1-10 mg/L, 10-20 mg/L, 20-40 mg/L, 40-60 mg/L, 60-80 mg/L, 80 ~100mg/L, 100~120mg/L, 120~140mg/L, 140~160mg/L, 160~180mg/L or 180~200mg/L.

在某些實施方案中，該水中的鎂含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~50mg/L、50~60mg/L、60~80mg/L或80~100mg/L。In certain embodiments, the magnesium content in the water is 0.1-1 mg/L, 1-10 mg/L, 10-20 mg/L, 20-40 mg/L, 40-50 mg/L, 50-60 mg/L, 60 ~80mg/L or 80~100mg/L.

在某些實施方案中，該水還包含以下元素中的一種或多種：鍶、鉀、鈉。In certain embodiments, the water further comprises one or more of the following elements: strontium, potassium, sodium.

在某些實施方案中，該水中的鍶、鉀、鈉分別以Sr2+ 、K+ 、Na+ 的形式存在。In certain embodiments, strontium, potassium, and sodium in the water are present in the form of Sr 2+ , K + , Na + , respectively.

在某些實施方案中，該水中的鍶含量為0.4~1.5mg/L，例如0.4~0.6mg/L、0.6~0.9mg/L、0.9~1.2mg/L或1.2~1.5mg/L。In certain embodiments, the strontium content in the water is 0.4-1.5 mg/L, such as 0.4-0.6 mg/L, 0.6-0.9 mg/L, 0.9-1.2 mg/L, or 1.2-1.5 mg/L.

在某些實施方案中，該水中的鉀含量為0.8~3mg/L，例如0.8~1mg/L、1~1.5mg/L、1.5~2mg/L或2~3mg/L。In certain embodiments, the potassium content in the water is 0.8-3 mg/L, such as 0.8-1 mg/L, 1-1.5 mg/L, 1.5-2 mg/L, or 2-3 mg/L.

在某些實施方案中，該水中的鈉含量為50~160mg/L，例如50~80mg/L、80~100mg/L、100~130mg/L或130~160mg/L。In certain embodiments, the sodium content in the water is 50-160 mg/L, such as 50-80 mg/L, 80-100 mg/L, 100-130 mg/L, or 130-160 mg/L.

在某些實施方案中，該水還包含偏矽酸。In certain embodiments, the water further comprises metasilicic acid.

在某些實施方案中，該水中的偏矽酸含量為6~20mg/L，例如6~8mg/L、8~9.5mg/L、9.5~12mg/L、12~15mg/L或15~20mg/L。In certain embodiments, the metasilicic acid content in the water is 6-20 mg/L, such as 6-8 mg/L, 8-9.5 mg/L, 9.5-12 mg/L, 12-15 mg/L, or 15-20 mg /L.

在某些實施方案中，該水還包含碳酸根和氯離子。In certain embodiments, the water further comprises carbonate and chloride ions.

在某些實施方案中，該水含有0.2~0.5mg/L鋰和4~20mg/L鈣，以及任選的鍶、鉀、鈉和/或偏矽酸。In certain embodiments, the water contains 0.2-0.5 mg/L lithium and 4-20 mg/L calcium, and optionally strontium, potassium, sodium and/or metasilicic acid.

在某些實施方案中，該水含有0.2~0.5mg/L鋰和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。In certain embodiments, the water contains 0.2-0.5 mg/L lithium and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid.

在某些實施方案中，該水含有0.2~0.5mg/L鋰，4~20mg/L鈣和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。In certain embodiments, the water contains 0.2-0.5 mg/L lithium, 4-20 mg/L calcium and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid.

在某些實施方案中，該水含有0.2~0.5mg/L鋰，0.4~1.5mg/L鍶，4~20mg/L鈣，1~6mg/L鎂，6~20mg/L偏矽酸，0.8~3mg/L鉀，以及50~160mg/L鈉。In certain embodiments, the water contains 0.2-0.5 mg/L lithium, 0.4-1.5 mg/L strontium, 4-20 mg/L calcium, 1-6 mg/L magnesium, 6-20 mg/L metasilicic acid, 0.8 ~3mg/L potassium, and 50~160mg/L sodium.

以上方法或用途中，該改善睡眠品質包括但不限於：縮短覺醒時間、延長累積睡眠時間、減少睡眠時相Wake所占百分比和/或增加睡眠時相NREM所占百分比。In the above methods or uses, the improving sleep quality includes, but is not limited to, shortening wake-up time, prolonging cumulative sleep time, reducing the percentage of sleep phase Wake and/or increasing the percentage of sleep phase NREM.

以上方法或用途中，該緩解睡眠障礙包括但不限於：改善由於睡眠環境變化、應激心理壓力、軀體疾病等原因引發的入睡困難、夜間易醒、多夢等症狀。In the above methods or uses, the alleviation of sleep disorders includes, but is not limited to, improving symptoms such as difficulty in falling asleep, easy waking up at night, and more dreams caused by changes in sleep environment, stressful psychological pressure, and physical diseases.

以上方法或用途中，該受試者包括人或非人動物，該非人動物包括脊椎動物，例如非哺乳動物(例如魚類、鳥類、兩棲動物、爬行動物)和哺乳動物，例如非人靈長類、家畜和/或馴化動物(例如鼠、綿羊、犬、貓、奶牛、豬等)。 有益效果In the above methods or uses, the subject includes a human or a non-human animal, the non-human animal includes vertebrates, such as non-mammals (eg, fish, birds, amphibians, reptiles) and mammals, such as non-human primates , livestock and/or domesticated animals (eg, rats, sheep, dogs, cats, cows, pigs, etc.). beneficial effect

發明人發現，含有特定含量鋰元素的飲用水具有改善睡眠的作用，同時含有特定含量的鋰、鈣以及鎂元素的飲用水對改善睡眠具有協同增效的作用。並且，針對因睡眠環境變化、應激心理壓力、軀體疾病等原因引發的入睡困難、夜間易醒、多夢等睡眠障礙的的人群，攝入本發明飲用水一定程度上可以改善睡眠品質。The inventors found that drinking water containing a specific content of lithium has the effect of improving sleep, and drinking water containing specific content of lithium, calcium and magnesium has a synergistic effect on improving sleep. In addition, for people with sleep disorders such as difficulty in falling asleep, easy waking up at night, and more dreams caused by changes in sleeping environment, stress psychological pressure, physical diseases, etc., drinking the drinking water of the present invention can improve sleep quality to a certain extent.

本發明的飲用水具有天然無毒，作用緩和，能夠改善睡眠品質的作用。The drinking water of the invention has the functions of natural non-toxicity, moderate effect and can improve sleep quality.

下面將結合以下試驗例，對本發明中的技術方案進行清楚、完整地描述，顯然，所描述的試驗例僅僅是本發明一部分實施例，而不是全部的實施例。基於本發明中的實施例，本領域普通技術人員所獲得的所有其他實施例，都屬本發明保護的範圍。 試驗例1  本發明輔助改善睡眠品質的人體試飲試驗 1.材料和方法 1.1受試對象The technical solutions in the present invention will be clearly and completely described below with reference to the following test examples. Obviously, the described test examples are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art fall within the protection scope of the present invention. Test Example 1 The human body drinking test of the present invention to assist in improving sleep quality 1. Materials and methods 1.1 Subjects

在浙江省杭州市範圍內，以自願為原則，募集年齡在18至60歲的健康人群為受試對象，共466名。經臨床體檢，非妊娠或哺乳期，排除嚴重的循環系統、代謝系統、泌尿系統、消化系統疾病，共得到150名受試者。 1.2受試者納入標準Within the scope of Hangzhou City, Zhejiang Province, a total of 466 healthy people aged 18 to 60 were recruited as subjects on a voluntary basis. A total of 150 subjects were obtained through clinical physical examination, not pregnant or lactating, excluding serious diseases of the circulatory system, metabolic system, urinary system, and digestive system. 1.2 Subject inclusion criteria

受試者性別不限，年齡在18-60歲，未參加過類似測試，近期無服用與改善睡眠品質相關的保健食品或藥品史，經臨床體檢，非妊娠或哺乳期，無嚴重的心腦血管疾病，無嚴重的循環系統疾病，無嚴重的代謝系統疾病，無嚴重的消化系統疾病，無嚴重的免疫系統疾病的基本健康受試者。 1.3受試者排除標準The subjects are not limited to gender, aged 18-60 years old, have not participated in similar tests, have no recent history of taking health food or drugs related to improving sleep quality, have undergone clinical physical examination, are not pregnant or breastfeeding, and have no serious heart disease. Basic healthy subjects without vascular disease, no serious circulatory system disease, no serious metabolic system disease, no serious digestive system disease, and no serious immune system disease. 1.3 Subject exclusion criteria

近期參加過類似測試，近期服用過與輔助改善睡眠品質有關的保健食品或藥品史，經臨床體檢，發現患有嚴重的心腦血管疾病，嚴重的循環系統疾病，嚴重的代謝系統疾病，嚴重的泌尿系統疾病，嚴重的消化系統疾病者，嚴重的免疫系統疾病者。 1.4實驗設計與分組Have participated in similar tests recently, have recently taken health food or drugs related to improving sleep quality, and have been found to have severe cardiovascular and cerebrovascular diseases, severe circulatory system diseases, severe metabolic system diseases, severe Urinary system disease, severe digestive system disease, severe immune system disease. 1.4 Experimental Design and Grouping

匹茲堡睡眠品質指數（Pittsburgh sleep quality index，PSQI）是美國匹茲堡大學精神科醫生Buysse博士等人於1989年編制的。該量表適用於睡眠障礙患者、精神障礙患者評價睡眠品質，同時也適用於一般人睡眠品質的評估。PSQI用於評定被試最近1個月的睡眠品質。由19個自評和5個他評條目構成，其中第19個自評條目和5個他評條目不參與計分。18個條目組成7個成份，每個成份按0～3等級計分，累積各成份得分為PSQI總分，總分範圍為0~2l，得分越高，表示睡眠品質越差。被試者完成試問需要5～10分鐘。The Pittsburgh sleep quality index (PSQI) was compiled in 1989 by Dr. Buysse, a psychiatrist at the University of Pittsburgh, USA. The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in ordinary people. PSQI was used to assess the sleep quality of the subjects in the last month. It consists of 19 self-assessment items and 5 other-assessment items, of which the 19th self-assessment item and 5 other-assessment items do not participate in scoring. The 18 items consist of 7 components, and each component is scored on a scale of 0 to 3. The cumulative score of each component is the total PSQI score, and the total score ranges from 0 to 2l. The higher the score, the worse the sleep quality. It took the subjects 5 to 10 minutes to complete the question.

對納入的受試者完成第一次匹茲堡睡眠品質指數量表測驗後，計算受試者的睡眠品質指數，在平衡了性別、年齡和職業等因素後，按睡眠品質指數，隨機分為2組，即對照組、和試飲組，各組均為75人。 1.5試飲劑量及飲用方法After the included subjects completed the first Pittsburgh sleep quality index scale test, the sleep quality index of the subjects was calculated. After balancing factors such as gender, age and occupation, they were randomly divided into two groups according to the sleep quality index. , namely the control group and the test group, each with 75 people. 1.5 Test dose and drinking method

各組每日均飲用1L本發明飲用水，試飲週期為30天。各組飲用水礦物質含量如下表1所示（實際生產出的不同批次的飲用水產品中，礦物質含量可以在一定範圍內波動，這在本領域是無法避免且可以被接受的）： 表1  飲用水產品主要礦物質元素含量 礦物物質濃度（mg/L） 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 試飲組 0.20~0.50mg/L 0.4~1.5mg/L 4.0~20.0mg/L 1.0~6.0mg/L 6.0~20.0mg/L 0.8~3.0mg/L 50~160mg/L Each group drank 1 L of the drinking water of the present invention every day, and the trial period was 30 days. The mineral content of drinking water in each group is shown in Table 1 below (in different batches of drinking water products actually produced, the mineral content can fluctuate within a certain range, which is unavoidable and acceptable in the art): Table 1 Contents of main mineral elements in drinking water products Mineral substance concentration (mg/L) lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 tasting group 0.20~0.50mg/L 0.4~1.5mg/L 4.0~20.0mg/L 1.0~6.0mg/L 6.0~20.0mg/L 0.8~3.0mg/L 50~160mg/L

受試期為30天。完成全程並參加第二次匹茲堡睡眠品質指數量表測驗的受試者有145人，有5人未參加第二次測驗，最後結果統計中對照組共72人，試飲組共73人。 2.結果 2.1受試者一般情況The trial period is 30 days. There were 145 subjects who completed the whole process and participated in the second Pittsburgh Sleep Quality Index Test, and 5 subjects did not participate in the second test. In the final statistics, there were 72 subjects in the control group and 73 subjects in the tasting group. 2. Results 2.1 General information of subjects

本次試飲試驗共有150人參加，在試飲過程中先後有5人退出，最後獲得有效資料為145人，其中對照組共72人，試飲組共73人。受試者在試飲期間沒有出現任何不良反應，部分受試者反應睡眠情況改善，各組受試者基本情況見表2。 表2  受試者一般情況    人數 男/女 平均年齡（歲） 平均身高（cm） 平均體重（kg） 對照組 72 38/34 42.8±3.6 163.4±6.8 61.2±7.6 試飲組1 73 38/35 43.2±2.5 165.6±5.3 62.4±6.8 2.2本發明對人體睡眠品質的影響A total of 150 people participated in the drinking test, and 5 people quit during the drinking process. Finally, 145 people got valid data, including 72 people in the control group and 73 people in the tasting group. The subjects did not experience any adverse reactions during the drinking test, and some subjects reported that their sleep conditions were improved. The basic conditions of subjects in each group are shown in Table 2. Table 2 General information of subjects number of people men and women Average age (years) Average height (cm) Average weight (kg) control group 72 38/34 42.8±3.6 163.4±6.8 61.2±7.6 tasting group 1 73 38/35 43.2±2.5 165.6±5.3 62.4±6.8 2.2 The influence of the present invention on human sleep quality

對各組受試者試驗前後匹茲堡品質指數量表進行資料統計。 表3  匹茲堡睡眠品質指數量表    人數 受試前 受試後 減少值 對照組 72 13.45±1.54 12.75±2.82 0.7±1.52 試飲組 75 13.55±1.73 6.54±1.36** 7.01±1.32** 注:*表示與對照組相比p＜0.05，**表示與對照組相比p＜0.01。Data statistics were performed on the Pittsburgh Quality Index Scale before and after the experiment in each group of subjects. Table 3 Pittsburgh Sleep Quality Index Scale number of people before the test after the test Decrease value control group 72 13.45±1.54 12.75±2.82 0.7±1.52 tasting group 75 13.55±1.73 6.54±1.36** 7.01±1.32** Note: * means p<0.05 compared with the control group, ** means p<0.01 compared with the control group.

各組飲用水對受試者匹茲堡睡眠品質指數的影響結果見表3。對照組受試前和受試後無顯著性差異。試飲組受試後匹茲堡睡眠品質指數顯著低於對照組（P＜0.01）；與受試前相比，試驗結束時試飲組匹茲堡睡眠品質指數比試驗前有顯著減少（P＜0.01）。 3.小結The effects of drinking water in each group on the Pittsburgh sleep quality index of the subjects are shown in Table 3. There was no significant difference between the control group before and after the test. After the test, the Pittsburgh sleep quality index of the drinking group was significantly lower than that of the control group (P<0.01). 3. Summary

受試者試飲本發明飲用水30天後，試飲組的匹茲堡睡眠品質指數顯著低於對照組（P＜0.01）。與試飲前相比，試驗結束時試飲組的匹茲堡睡眠品質指數比試驗前有顯著降低（P＜0.01）；說明試飲組受試者的睡眠品質得到有效改善。試飲組飲用水主要礦物質元素為：鋰0.2~0.5mg/L，鍶0.4~1.5mg/L，鈣4.0~20.0mg/L，鎂1.0~6.0mg/L，偏矽酸濃度為6.0~20.0mg/L，鉀濃度為0.8~3.0mg/L，鈉濃度為50~160mg/L；與對照組（礦物質元素含量為零）相比，可以推斷試飲組中富含的礦物質元素，是改善受試者睡眠功能的主要原因。因此可得出結論：每日飲用1L鋰濃度為0.2~0.5mg/L、鍶濃度為0.4~1.5mg/L，鈣濃度為4.0~20.0mg/L，鎂濃度為1.0~6.0mg/L，偏矽酸濃度為6.0~20.0mg/L，鉀濃度為0.8~3.0mg/L，鈉濃度為50~160mg/L的飲用水可以改善睡眠品質。After the subjects tried drinking the drinking water of the present invention for 30 days, the Pittsburgh sleep quality index of the test group was significantly lower than that of the control group (P<0.01). Compared with before the test, the Pittsburgh sleep quality index of the test group at the end of the test was significantly lower than that before the test (P<0.01), indicating that the sleep quality of the test group was effectively improved. The main mineral elements in drinking water of the test group were: lithium 0.2~0.5mg/L, strontium 0.4~1.5mg/L, calcium 4.0~20.0mg/L, magnesium 1.0~6.0mg/L, and the concentration of metasilicic acid was 6.0~20.0 mg/L, potassium concentration is 0.8~3.0mg/L, sodium concentration is 50~160mg/L; compared with the control group (mineral element content is zero), it can be inferred that the rich mineral elements in the test group are The main reason for improving the sleep function of the subjects. Therefore, it can be concluded that the concentration of lithium, 0.4 to 1.5 mg/L of strontium, 4.0 to 20.0 mg/L of calcium, 1.0 to 6.0 mg/L of magnesium, and 1.0 to 6.0 mg/L of magnesium per day. Drinking water with a metasilicic acid concentration of 6.0-20.0 mg/L, a potassium concentration of 0.8-3.0 mg/L, and a sodium concentration of 50-160 mg/L can improve sleep quality.

試驗例2~28具體實驗方法如下所示。The specific experimental methods of Test Examples 2 to 28 are shown below.

飲用水樣品製備方法：按照實驗所需礦物質濃度分別將碳酸鋰、氯化鈣、氯化鎂、氯化鍶、氯化鉀、氯化鈉、偏矽酸鈉溶解至蒸餾水中，攪拌至完全溶解後，過濾除菌後，在無菌條件下罐裝至無菌樣品瓶中。Drinking water sample preparation method: Dissolve lithium carbonate, calcium chloride, magnesium chloride, strontium chloride, potassium chloride, sodium chloride, and sodium metasilicate into distilled water according to the mineral concentrations required by the experiment, and stir until completely dissolved. , after filter sterilization, filled into sterile sample vials under aseptic conditions.

動物實驗飼養條件：雄性ICR小鼠（25±2g），購自浙江省醫學科學院，進行7天的預備飼養後進行實驗飼養。小鼠的飼養條件為溫度23±1℃、濕度55±10％、動物飼養中心採取放 40W 日光燈模擬自然光照射，12 小時自動切換光照（6:00-18:00）、黑暗模擬自然晝夜切換，小鼠自由攝取水和飼料。實驗飼料使用小鼠生長穩定飼料（國標M2118），動物的日常飼養管理由動物保障部負責，每日為動物提供足夠的塊料和新鮮的飲用水。各組小鼠適應結束後進行多導睡眠圖記錄的外科手術實驗。在接受治療前後，動物至少應保持不受干擾48小時。Animal experimental feeding conditions: Male ICR mice (25 ± 2 g), purchased from Zhejiang Academy of Medical Sciences, were subjected to experimental feeding after 7 days of preparatory feeding. The rearing conditions of mice were temperature 23±1℃, humidity 55±10%, 40W fluorescent lamp was placed in the animal breeding center to simulate natural light irradiation, 12 hours of automatic switching of light (6:00-18:00), and darkness to simulate natural day and night switching. Mice had free access to water and chow. The experimental feed used stable growth feed for mice (national standard M2118), and the animal security department was responsible for the daily feeding and management of the animals, and provided enough blocks and fresh drinking water for the animals every day. After the adaptation of mice in each group, the surgical experiment of polysomnography recording was performed. Animals should remain undisturbed for at least 48 hours before and after treatment.

多導睡眠圖記錄的外科手術實驗：小鼠藉由2％異氟烷麻醉而麻醉，並用顱骨植入物進行手術製備，以記錄慢性腦電圖（EEG）和肌電圖（EMG）。用4％異氟烷麻醉動物，剃去頭皮，並將頭固定在立體定位儀中。切開手術局部的皮膚和結締組織後，局部採用碘伏消毒，並借助腦立體定位儀確定 Bregma 點，使用電刀頂點在顱骨燒灼做局部標記，以便後續定位；用電凝刀在此前標記定位點處鑽開顱骨，要充分考慮小鼠顱骨的厚度較薄，儘量選擇多操作幾次，避免腦實質的損傷，暴露局部傷口，並使用碘伏消毒棉球再次清潔並消毒術野；在鑽出顱骨開口處放入電極，使用牙科水泥將頭部電極固定於顱骨；將兩根無菌導線穿過頭後頸肌，從而實現對頸部肌電活動的監測；最後，縫合皮膚，並將動物從立體定位儀中取出。術後將實驗動物置於有機玻璃籠內，置於小鼠皮層腦電檢測室內單獨飼養。採取術後護理措施，連續3d腹腔注射40000U青黴素以控制動物感染和腦部炎症，動物恢復兩週後參與實驗。Surgical experiments for polysomnographic recordings: Mice were anesthetized with 2% isoflurane and surgically prepared with cranial implants for chronic electroencephalogram (EEG) and electromyography (EMG) recordings. Animals were anesthetized with 4% isoflurane, the scalp was shaved, and the head was fixed in a stereotaxic apparatus. After incision of the skin and connective tissue in the surgical site, the local area was sterilized with iodophor, and the Bregma point was determined with the aid of a brain stereotaxic instrument, and the top of the electrocautery was used to cauterize the skull to make a local mark for subsequent positioning; the electrocautery knife was used to mark the positioning point before. When drilling the skull, the thickness of the mouse skull should be fully considered, and the operation should be performed as many times as possible to avoid damage to the brain parenchyma, expose the local wound, and use an iodophor sterile cotton ball to clean and disinfect the surgical field again; Electrodes were placed at the opening of the skull, and the head electrodes were fixed to the skull using dental cement; two sterile wires were passed through the head and neck muscles to monitor the electromyographic activity of the neck; finally, the skin was sutured, and the animal was removed from the stereotaxic position. removed from the locator. After the operation, the experimental animals were placed in plexiglass cages and housed separately in the mouse cortex EEG testing room. Postoperative care measures were taken, and 40,000 U of penicillin was injected intraperitoneally for 3 days to control animal infection and brain inflammation. Animals participated in the experiment after two weeks of recovery.

睡眠電極訊號收集：連接資料收集系統介面和小鼠頭部電極，使用 MP100 資料收集系統(MP100A-CE; Biopac Systems, Santa Barbara, CA)對小鼠的 EEG 和 EMG 訊號進行收集，之後採用 Biopac Acqknowledge 軟件(version 3.7.3; Biopac Systems)對其記錄和圖像化顯示。記錄時間選擇 18:00 至第二天 18:00，記錄相應的睡眠腦電和肌肉活動電生理資料。Sleep electrode signal collection: Connect the data collection system interface to the mouse head electrode, use the MP100 data collection system (MP100A-CE; Biopac Systems, Santa Barbara, CA) to collect the EEG and EMG signals of the mice, and then use Biopac Acqknowledge Software (version 3.7.3; Biopac Systems) recorded and visualized it. The recording time was selected from 18:00 to 18:00 the next day, and the corresponding sleep EEG and muscle activity electrophysiological data were recorded.

睡眠記錄腦電的分析方法：(1)應用 Sleep Sign for Animals 軟件(version 3.0, Kissei)收集 24 小時睡眠及覺醒期的 EEG 訊號和頸部肌肉活動 EMG 訊號；(2)判讀採用使用 4s/幀的逐幀判讀，結合小鼠的 EEG 和 EMG 訊號進行判讀，睡眠狀態的判斷採用機器算法自動判讀和人工修正相結合的方法；(3)根據已有關於小鼠睡眠腦電判讀相關標準，將小鼠的睡眠和覺醒狀態分為三種狀態：覺醒（Wake）、非快速眼動期（NREM）睡眠和快速眼動期（REM）睡眠；(4)覺醒期的主要判讀標準為腦電中出現低波幅，混合頻率電活動，其中每幀中 delta 波比例少於 30%，同時伴有相對高幅的肌電活動；(5)非快速眼動期睡眠的主要判讀標準是慢波活動相對較多，慢波多集中在 0-4Hz，其中 delta 波在每幀中比例一般小於 30%，同時肌電圖的也出現較低幅度的電活動；(6)快速眼動期睡眠的主要判讀標準是腦電圖中較高頻出現 theta波，其中 theta波多表現為 5-10 Hz，通常 delta 波在每一幀腦電圖中的比例小於 20%，theta波在每一幀腦電圖中的比例大於 30%，在此其睡眠中肌電圖活動表現為極低幅度的電活動或趨近於基線；(7)腦電圖中 delta 波、theta 波以及肌電活動的閾值一般需要參照多隻小鼠的值進行人工判讀，劃定標準，此後再參照此標準對機器進行校準，並結合機器的算法進行自動判讀，機器判讀後人工必須再進行逐幀修正，得到相對準確的睡眠狀態判斷。The analysis method of sleep recording EEG: (1) The Sleep Sign for Animals software (version 3.0, Kissei) was used to collect EEG signals and neck muscle activity EMG signals during 24 hours of sleep and wakefulness; (2) 4s/frame was used for interpretation. The frame-by-frame interpretation of the mouse is combined with the EEG and EMG signals of the mouse, and the sleep state is judged by a combination of automatic interpretation by machine algorithm and manual correction; (3) According to the existing relevant standards for the interpretation of sleep EEG in mice, the The sleep and wakefulness states of mice are divided into three states: wake (Wake), non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep; (4) The main interpretation standard of wakefulness is the appearance in EEG. Low-amplitude, mixed-frequency electrical activity, in which the proportion of delta waves in each frame is less than 30%, accompanied by relatively high-amplitude EMG activity; (5) The main criterion for interpreting non-REM sleep is that the slow-wave activity is relatively high. Most of the slow waves are concentrated in 0-4Hz, in which the proportion of delta waves in each frame is generally less than 30%, and the electromyogram also shows lower amplitude electrical activity; (6) The main interpretation standard of REM sleep is Theta waves appear at a higher frequency in the EEG, and the theta waves are mostly 5-10 Hz. Usually, the proportion of delta waves in each frame of EEG is less than 20%, and the proportion of theta waves in each frame of EEG More than 30%, the EMG activity in sleep is shown as very low amplitude electrical activity or close to the baseline; (7) The thresholds of delta wave, theta wave and EMG activity in EEG generally need to refer to multiple The value of the mouse is manually interpreted and a standard is defined. After that, the machine is calibrated with reference to this standard, and it is automatically interpreted in combination with the algorithm of the machine. After the machine's interpretation, the manual correction must be performed frame by frame to obtain a relatively accurate sleep state judgment.

睡眠記錄的判讀指標和統計分析方法：（1）記錄開始及結束時間、睡眠總時間、Wake、NREM、REM 等各分期睡眠時間，並結合開燈和關燈（6:00/18:00）時間，得出開、關燈期各睡眠狀態和持續時間的資料；（2）對所得資料以使用 Microsoft Excel 2007、Graphpad Prism7.0 軟件收集和整理，最終數值以均數±標準差表示；（3）資料的統計分析採用重複測量資料的 2way ANOVA 方法，多組間進行Tukey 檢驗，以 p＜0.05 為顯著性水準。 試驗例2  飲用水改善睡眠功效的動物驗證試驗Interpretation indicators and statistical analysis methods of sleep records: (1) Record start and end time, total sleep time, sleep time of each stage such as Wake, NREM, REM, etc., and combine lights on and off (6:00/18:00) (2) Collect and organize the obtained data using Microsoft Excel 2007 and Graphpad Prism7.0 software, and the final value is expressed as mean ± standard deviation; ( 3) Statistical analysis of the data adopts the 2way ANOVA method of repeated measures data, and conducts Tukey's test among multiple groups, with p<0.05 as the level of significance. Test Example 2 Animal verification test of the effect of drinking water on improving sleep

取小鼠135隻，隨機分成9組，分別為對照組和8組受試樣品組。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。對照組動物給樣品組同等體積的無菌蒸餾水。各組飲用水礦物質濃度如表4所示。 表4  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.5 0.6 100 50 9.5 1.5 100 樣品組2 0 0.6 100 50 9.5 1.5 100 樣品組3 0.5 0 100 50 9.5 1.5 100 樣品組4 0.5 0.6 0 50 9.5 1.5 100 樣品組5 0.5 0.6 100 0 9.5 1.5 100 樣品組6 0.5 0.6 100 50 0 1.5 100 樣品組7 0.5 0.6 100 50 9.5 0 100 樣品組8 0.5 0.6 100 50 9.5 1.5 0 注:*表示p＜0.05，**表示p＜0.01。A total of 135 mice were randomly divided into 9 groups, namely the control group and the 8 test sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Animals in the control group were given the same volume of sterile distilled water in the sample group. The mineral concentrations of drinking water in each group are shown in Table 4. Table 4 The main mineral composition of drinking water used in the experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.5 0.6 100 50 9.5 1.5 100 Sample set 2 0 0.6 100 50 9.5 1.5 100 Sample set 3 0.5 0 100 50 9.5 1.5 100 Sample set 4 0.5 0.6 0 50 9.5 1.5 100 Sample set 5 0.5 0.6 100 0 9.5 1.5 100 Sample set 6 0.5 0.6 100 50 0 1.5 100 Sample set 7 0.5 0.6 100 50 9.5 0 100 Sample set 8 0.5 0.6 100 50 9.5 1.5 0 Note: * means p<0.05, ** means p<0.01.

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表5所示。 表5  動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 250.65±7.45** 34.81%±1.03%** 425.90±10.94** 59.15%±1.52** 43.45±3.08 6.03%±0.43% 樣品組2 319.42±12.65 44.36%±1.76% 356.22±15.46 49.48%±2.15% 44.36±2.86 6.16%±0.40% 樣品組3 267.76±10.88** 37.19%±1.51%** 412.65±13.28** 57.31%±1.84%** 39.59±2.95 5.50%±0.41% 樣品組4 310.14±11.45* 43.08%±1.59% 366.13±14.75* 50.85%±2.05% 43.73±2.05 6.07%±0.28% 樣品組5 307.56±13.46* 42.72%±1.87% 370.80±12.55* 51.50%±1.74% 41.64±3.22 5.78%±0.45% 樣品組6 265.77±12.85** 36.91%±1.78%** 414.55±14.99** 57.58%±2.08%** 39.68±2.12 5.51%±0.29% 樣品組7 270.03±12.22** 37.50%±1.70%** 408.76±12.30** 56.77%±1.71%** 41.21±2.98 5.72%±0.41% 樣品組8 258.85±11.92** 35.95%±1.66%** 418.65±11.92** 58.15%±1.66%** 42.5±2.5 5.90%±0.35% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 5. Table 5 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 250.65±7.45** 34.81%±1.03%** 425.90±10.94** 59.15%±1.52** 43.45±3.08 6.03%±0.43% Sample set 2 319.42±12.65 44.36%±1.76% 356.22±15.46 49.48%±2.15% 44.36±2.86 6.16%±0.40% Sample set 3 267.76±10.88** 37.19%±1.51%** 412.65±13.28** 57.31%±1.84%** 39.59±2.95 5.50%±0.41% Sample set 4 310.14±11.45* 43.08%±1.59% 366.13±14.75* 50.85%±2.05% 43.73±2.05 6.07%±0.28% Sample set 5 307.56±13.46* 42.72%±1.87% 370.80±12.55* 51.50%±1.74% 41.64±3.22 5.78%±0.45% Sample set 6 265.77±12.85** 36.91%±1.78%** 414.55±14.99** 57.58%±2.08%** 39.68±2.12 5.51%±0.29% Sample set 7 270.03±12.22** 37.50%±1.70%** 408.76±12.30** 56.77%±1.71%** 41.21±2.98 5.72%±0.41% Sample set 8 258.85±11.92** 35.95%±1.66%** 418.65±11.92** 58.15%±1.66%** 42.5±2.5 5.90%±0.35% Note: * means p<0.05, ** means p<0.01.

藉由表4、表5分析可知，與對照組相比，樣品組1、樣品組3、樣品組6、樣品組7、樣品組8動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間（總觀測週期12h減去覺醒時間，下同）明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1、樣品組3、樣品組6、樣品組7、樣品組8動物攝入飲用水30天後睡眠情況得到明顯改善。與對照組相比，樣品組4、樣品組5動物覺醒時間一定程度上縮短（p＜0.05），累積睡眠時間一定程度上延長（p＜0.05）；說明樣品組4、樣品組5動物攝入飲用水30天後睡眠情況得到一定改善。樣品組2動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯。According to the analysis of Table 4 and Table 5, compared with the control group, the wake-up time of the animals in sample group 1, sample group 3, sample group 6, sample group 7 and sample group 8 was significantly shortened (p < 0.01), and the cumulative sleep time ( The total observation period of 12h minus the awakening time, the same below) was significantly prolonged (p<0.01), the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01); It shows that the sleep conditions of the animals in sample group 1, sample group 3, sample group 6, sample group 7, and sample group 8 have been significantly improved after consuming drinking water for 30 days. Compared with the control group, the awakening time of the animals in sample group 4 and sample group 5 was shortened to a certain extent (p < 0.05), and the cumulative sleep time was prolonged to a certain extent (p < 0.05). After 30 days of drinking water, the sleep situation improved to some extent. Compared with the control group, there was no significant difference in the wake-up time and accumulated sleep time of the animals in the sample group 2, and the sleep phase changes were not obvious.

與對照組相比，樣品組1含有0.5mg/L鋰、0.6mg/L鍶、100mg/L鈣、50mg/L鎂、9.5mg/L偏矽酸、1.5mg/L鉀、100mg/L鈉。說明含有0.5mg/L鋰、0.6mg/L鍶、100mg/L鈣、50mg/L鎂、9.5mg/L偏矽酸、1.5mg/L鉀、100mg/L鈉的礦物質飲用水具有改善睡眠的作用。Compared with the control group, sample group 1 contained 0.5mg/L lithium, 0.6mg/L strontium, 100mg/L calcium, 50mg/L magnesium, 9.5mg/L metasilicic acid, 1.5mg/L potassium, 100mg/L sodium . Description Mineral drinking water containing 0.5mg/L lithium, 0.6mg/L strontium, 100mg/L calcium, 50mg/L magnesium, 9.5mg/L metasilicic acid, 1.5mg/L potassium, 100mg/L sodium improves sleep effect.

值得注意的是，樣品組2與樣品組1相比缺少0.5mg/L鋰元素，而樣品組2動物攝入30天後沒有發現改善睡眠的作用；可以推斷鋰元素可能是本發明飲用水中改善睡眠作用的關鍵礦物質元素。而與樣品組1相比，樣品組4缺少100mg/L鈣元素；樣品組5缺少50mg/L鎂元素，兩組雖然有一定程度改善睡眠的作用，但延長累積睡眠時間和增加NREM時相比例沒有樣品組1效果好。可以推斷，鈣元素與鎂元素對改善睡眠作用有一定的影響。樣品組3、樣品組6、樣品組7、樣品組8與樣品組1改善睡眠作用無明顯差別，與樣品組1相比，樣品組3樣品組6、樣品組7、樣品組8分別缺少0.6mg/L鍶、9.5mg/L偏矽酸、1.5mg/L鉀、100mg/L鈉。可以推斷，飲用水中鍶、偏矽酸、鉀以及鈉元素對改善睡眠作用可能沒有直接的影響。It is worth noting that compared with the sample group 1, the sample group 2 lacked 0.5 mg/L lithium element, and the animals in the sample group 2 did not find the effect of improving sleep after 30 days of intake; it can be inferred that lithium element may be in the drinking water of the present invention. Key minerals for improving sleep. Compared with sample group 1, sample group 4 lacked 100 mg/L calcium; sample group 5 lacked 50 mg/L magnesium. Although the two groups improved sleep to a certain extent, the proportion of prolonged cumulative sleep time and increased NREM No sample group 1 worked as well. It can be inferred that calcium and magnesium elements have a certain influence on improving sleep. Compared with sample group 1, sample group 3, sample group 6, sample group 7 and sample group 8 lacked 0.6 mg/L strontium, 9.5mg/L metasilicic acid, 1.5mg/L potassium, 100mg/L sodium. It can be inferred that strontium, metasilicic acid, potassium and sodium in drinking water may not have a direct effect on improving sleep.

以上結果可以說明，在本發明飲用水礦物質中鋰元素、鈣元素與鎂元素是本發明飲用水中改善睡眠品質的重要元素。在後續的試驗例中，在其他礦物質元素濃度不變的情況下，我們重點考察鋰元素、鈣元素以及鎂元素對動物睡眠品質的影響。 試驗例3  飲用水改善睡眠功效的動物驗證試驗The above results can illustrate that lithium, calcium and magnesium in the drinking water minerals of the present invention are important elements for improving sleep quality in the drinking water of the present invention. In the subsequent test cases, we focused on the effects of lithium, calcium and magnesium on the sleep quality of animals under the condition that the concentrations of other mineral elements remained unchanged. Test Example 3 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表6所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表6  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.1 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 0.1 0 9.5 1.5 100 樣品組3 0 0.6 0 0.1 9.5 1.5 100 樣品組4 0.1 0.6 0.1 0 9.5 1.5 100 樣品組5 0.1 0.6 0 0.1 9.5 1.5 100 樣品組6 0.1 0.6 0.1 0.1 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentration of each mineral in the drinking water for gavage of the 6 sample groups is shown in Table 6, and the animals in the control group were given the same volume of sterile distilled water in the sample group. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 6 Composition of main minerals in drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.1 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 0.1 0 9.5 1.5 100 Sample set 3 0 0.6 0 0.1 9.5 1.5 100 Sample set 4 0.1 0.6 0.1 0 9.5 1.5 100 Sample set 5 0.1 0.6 0 0.1 9.5 1.5 100 Sample set 6 0.1 0.6 0.1 0.1 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表7所示。 表7  動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% 樣品組2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% 樣品組3 327.76±13.28 45.52%±1.84%** 350.65±13.56** 48.70%±1.88%** 41.59±2.75 5.78%±0.38% 樣品組4 269.45±10.22** 37.42%±1.42% 408.35±15.66** 56.72%±2.18%** 42.20±2.89 5.86%±0.40% 樣品組5 271.34±11.54** 37.69%±1.60%** 406.67±14.76** 56.48%±2.05%** 41.99±2.56 5.83%±0.36% 樣品組6 272.64±10.45** 37.87%±1.45%** 405.17±14.75** 56.27%±2.05%** 42.19±2.72 5.86%±0.38% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed, and the statistical time period was from 6:00 to 18:00 every day. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 7. Table 7 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% Sample set 2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% Sample set 3 327.76±13.28 45.52%±1.84%** 350.65±13.56** 48.70%±1.88%** 41.59±2.75 5.78%±0.38% Sample set 4 269.45±10.22** 37.42%±1.42% 408.35±15.66** 56.72%±2.18%** 42.20±2.89 5.86%±0.40% Sample set 5 271.34±11.54** 37.69%±1.60%** 406.67±14.76** 56.48%±2.05%** 41.99±2.56 5.83%±0.36% Sample set 6 272.64±10.45** 37.87%±1.45%** 405.17±14.75** 56.27%±2.05%** 42.19±2.72 5.86%±0.38% Note: * means p<0.05, ** means p<0.01.

藉由表6、表7結果分析可知，與對照組相比，樣品組2（含0.1 mg/L鈣元素）、樣品組3（含0.1 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.1mg/L鋰+0.1 mg/L鈣+0.1 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 6 and Table 7, it can be seen that compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 0.1 mg/L calcium) and sample group 3 (containing 0.1 mg/L magnesium) were significantly different from those in the control group. Compared with the control group, there was no significant difference, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after consuming mineral drinking water for 30 days. Sample group 1 (containing 0.1 mg/L lithium) and sample group 4 (containing 0.1 mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 0.1 mg/L magnesium) element) and sample group 6 (containing 0.1 mg/L lithium + 0.1 mg/L calcium + 0.1 mg/L magnesium), the awakening time of animals was significantly shortened (p < 0.01), the cumulative sleep time was significantly prolonged (p < 0.01), sleep The percentage of Wake in the phase decreased significantly (p < 0.01), and the percentage of NREM in the sleep phase increased significantly (p < 0.01). /L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 0.1 mg/L magnesium) and sample group 6 (containing 0.1 mg/L lithium + 0.1 mg/L calcium) element + 0.1 mg/L magnesium element) the sleep situation of the animals was improved after 30 days of ingesting the drinking water of the present invention.

與樣品組1（含0.1mg/L鋰元素）單獨攝入相比，樣品組4（含0.1mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著；且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.1mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.1mg/L鋰元素與0.1 mg/L鈣元素或0.1 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例4  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 0.1 mg/L lithium element) alone, sample group 4 (containing 0.1 mg/L lithium element + 0.1 mg/L calcium element), sample group 5 (containing 0.1 mg/L lithium element) +0.1 mg/L magnesium) and sample group 6 (containing 0.1 mg/L lithium + 0.1 mg/L calcium + 0.1 mg/L magnesium) combined intake has a more significant effect on improving sleep; and the sample group 4. There is no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.1 mg/L lithium has the effect of improving sleep; the combined use of 0.1 mg/L lithium and 0.1 mg/L calcium or 0.1 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 4 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表8所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表8  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 0.1 0 9.5 1.5 100 樣品組3 0 0.6 0 0.1 9.5 1.5 100 樣品組4 0.5 0.6 0.1 0 9.5 1.5 100 樣品組5 0.5 0.6 0 0.1 9.5 1.5 100 樣品組6 0.5 0.6 0.1 0.1 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 groups of sample groups are shown in Table 8, and the animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 8 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 0.1 0 9.5 1.5 100 Sample set 3 0 0.6 0 0.1 9.5 1.5 100 Sample set 4 0.5 0.6 0.1 0 9.5 1.5 100 Sample set 5 0.5 0.6 0 0.1 9.5 1.5 100 Sample set 6 0.5 0.6 0.1 0.1 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表9所示。 表9 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% 樣品組2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% 樣品組3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% 樣品組4 267.73±12.25** 37.18%±1.70%** 411.55±15.53** 57.16%±2.16%** 40.72±3.12 5.66%±0.43% 樣品組5 264.05±13.68** 36.67%±1.90%** 415.24±14.98** 57.67%±2.08%** 40.71±2.98 5.65%±0.41% 樣品組6 265.02±10.59** 36.81%±1.47%** 413.49±16.55** 57.43%±2.30%** 41.49±3.02 5.76%±0.42% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 9. Table 9 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% Sample set 2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% Sample set 3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% Sample set 4 267.73±12.25** 37.18%±1.70%** 411.55±15.53** 57.16%±2.16%** 40.72±3.12 5.66%±0.43% Sample set 5 264.05±13.68** 36.67%±1.90%** 415.24±14.98** 57.67%±2.08%** 40.71±2.98 5.65%±0.41% Sample set 6 265.02±10.59** 36.81%±1.47%** 413.49±16.55** 57.43%±2.30%** 41.49±3.02 5.76%±0.42% Note: * means p<0.05, ** means p<0.01.

藉由表8、表9結果分析可知，與對照組相比，樣品組2（含0.1 mg/L鈣元素）、樣品組3（含0.1 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。According to the analysis of the results in Table 8 and Table 9, compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 0.1 mg/L calcium) and sample group 3 (containing 0.1 mg/L magnesium) were significantly different from those in the control group. Compared with the control group, there was no significant difference, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after consuming mineral drinking water for 30 days. Sample group 1 (containing 0.5 mg/L lithium) and sample group 4 (containing 0.5 mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 0.1 mg/L magnesium) element) and sample group 6 (containing 0.5mg/L lithium element + 0.1 mg/L calcium element + 0.1 mg/L magnesium element) the wake-up time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.5mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 0.1 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 0.1 mg/L L calcium element + 0.1 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含0.5mg/L鋰元素）單獨攝入相比，樣品組4（含0.5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.5mg/L鋰元素與0.1 mg/L鈣元素或0.1 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例5  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 0.5mg/L lithium element) alone, sample group 4 (containing 0.5 mg/L lithium element + 0.1 mg/L calcium element), sample group 5 (containing 0.5 mg/L lithium element) +0.1 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 0.1 mg/L calcium + 0.1 mg/L magnesium) combined intake has a more significant effect on improving sleep, and the sample group 4. There is no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.5mg/L lithium has the effect of improving sleep; the combined use of 0.5mg/L lithium and 0.1 mg/L calcium or 0.1 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 5 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表10所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表10  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 0.1 0 9.5 1.5 100 樣品組3 0 0.6 0 0.1 9.5 1.5 100 樣品組4 5 0.6 0.1 0 9.5 1.5 100 樣品組5 5 0.6 0 0.1 9.5 1.5 100 樣品組6 5 0.6 0.1 0.1 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 sample groups are shown in Table 10, and the animals in the control group were given the same volume of sterile distilled water in the sample group. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 10 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 0.1 0 9.5 1.5 100 Sample set 3 0 0.6 0 0.1 9.5 1.5 100 Sample set 4 5 0.6 0.1 0 9.5 1.5 100 Sample set 5 5 0.6 0 0.1 9.5 1.5 100 Sample set 6 5 0.6 0.1 0.1 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表11所示。 表11 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% 樣品組2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% 樣品組3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% 樣品組4 261.64±10.68** 36.34%±1.48%** 418.87±15.34** 58.18%±2.13%** 39.49±4.86 5.48%±0.68% 樣品組5 262.75±11.79** 36.49%±1.64%** 416.63±14.96** 57.87%±2.08%** 40.62±4.56 5.64%±0.63% 樣品組6 260.72±9.57** 36.21%±1.33%** 419.40±16.87** 58.25%±2.34%** 39.88±4.72 5.54%±0.66% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 11. Table 11 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% Sample set 2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% Sample set 3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% Sample set 4 261.64±10.68** 36.34%±1.48%** 418.87±15.34** 58.18%±2.13%** 39.49±4.86 5.48%±0.68% Sample set 5 262.75±11.79** 36.49%±1.64%** 416.63±14.96** 57.87%±2.08%** 40.62±4.56 5.64%±0.63% Sample set 6 260.72±9.57** 36.21%±1.33%** 419.40±16.87** 58.25%±2.34%** 39.88±4.72 5.54%±0.66% Note: * means p<0.05, ** means p<0.01.

藉由表10、表11結果分析可知，與對照組相比，樣品組2（含0.1 mg/L鈣元素）、樣品組3（含0.1 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+0.1 mg/L鎂元素）、樣品組6（含5mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+0.1 mg/L鎂元素）、樣品組6（含5mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 10 and Table 11, it can be seen that compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 0.1 mg/L calcium) and sample group 3 (containing 0.1 mg/L magnesium) were significantly different from those in the control group. Compared with the control group, there was no significant difference, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after consuming mineral drinking water for 30 days. Sample group 1 (containing 5 mg/L lithium) and sample group 4 (containing 5 mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 0.1 mg/L magnesium), In sample group 6 (containing 5 mg/L lithium element + 0.1 mg/L calcium element + 0.1 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01). The percentage of Wake was significantly decreased (p < 0.01), and the percentage of NREM during sleep was significantly increased (p < 0.01). +0.1 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 0.1 mg/L magnesium), sample group 6 (containing 5 mg/L lithium + 0.1 mg/L calcium + 0.1 mg/L Magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含5mg/L鋰元素）單獨攝入相比，樣品組4（含5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+0.1 mg/L鎂元素）、樣品組6（含5mg/L鋰元素+0.1 mg/L鈣元素+0.1 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中5mg/L鋰元素與0.1 mg/L鈣元素或0.1 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例6  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 5mg/L lithium element) alone, sample group 4 (containing 5mg/L lithium element + 0.1 mg/L calcium element), sample group 5 (containing 5 mg/L lithium element + 0.1 mg /L magnesium), sample group 6 (containing 5mg/L lithium + 0.1 mg/L calcium + 0.1 mg/L magnesium) combined intake has a more significant effect on improving sleep, and sample group 4, sample group There was no significant difference between 5 and sample group 6. It can be shown that drinking water containing 5mg/L lithium has the effect of improving sleep; the combined use of 5mg/L lithium and 0.1 mg/L calcium or 0.1 mg/L magnesium in drinking water has a synergistic effect on improving sleep effect. Test Example 6 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表12所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表12 實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.1 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 200 0 9.5 1.5 100 樣品組3 0 0.6 0 0.1 9.5 1.5 100 樣品組4 0.1 0.6 200 0 9.5 1.5 100 樣品組5 0.1 0.6 0 0.1 9.5 1.5 100 樣品組6 0.1 0.6 200 0.1 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 sample groups are shown in Table 12, and the animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 12 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.1 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 200 0 9.5 1.5 100 Sample set 3 0 0.6 0 0.1 9.5 1.5 100 Sample set 4 0.1 0.6 200 0 9.5 1.5 100 Sample set 5 0.1 0.6 0 0.1 9.5 1.5 100 Sample set 6 0.1 0.6 200 0.1 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表13所示。 表13 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% 樣品組2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% 樣品組3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% 樣品組4 268.46±12.32** 37.29%±1.71%** 409.24±12.88** 56.84%±1.79%** 42.30±2.86 5.88%±0.40% 樣品組5 272.42±13.54** 37.84%±1.88%** 405.65±12.52** 56.34%±1.74%** 41.93±2.99 5.82%±0.42% 樣品組6 270.84±10.95** 37.62%±1.52%** 407.10±13.05** 56.54%±1.81%** 42.06±2.72 5.84%±0.38% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed, and the statistical time period was from 6:00 to 18:00 every day. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 13. Table 13 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% Sample set 2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% Sample set 3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% Sample set 4 268.46±12.32** 37.29%±1.71%** 409.24±12.88** 56.84%±1.79%** 42.30±2.86 5.88%±0.40% Sample set 5 272.42±13.54** 37.84%±1.88%** 405.65±12.52** 56.34%±1.74%** 41.93±2.99 5.82%±0.42% Sample set 6 270.84±10.95** 37.62%±1.52%** 407.10±13.05** 56.54%±1.81%** 42.06±2.72 5.84%±0.38% Note: * means p<0.05, ** means p<0.01.

藉由表12、表13結果分析可知，與對照組相比，樣品組2（含200mg/L鈣元素）、樣品組3（含0.1 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+0.1 mg/L鎂元素）、樣品組6（含0.1mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+0.1 mg/L鎂元素）、樣品組6（含0.1mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。According to the analysis of the results in Table 12 and Table 13, compared with the control group, the awakening time and cumulative sleep time of the animals in sample group 2 (containing 200 mg/L calcium) and sample group 3 (containing 0.1 mg/L magnesium) were compared with the control group. There was no significant difference between the groups, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after ingesting mineral drinking water for 30 days. Sample group 1 (containing 0.1 mg/L lithium) and sample group 4 (containing 0.1 mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 0.1 mg/L magnesium) element), sample group 6 (containing 0.1 mg/L lithium element + 200 mg/L calcium element + 0.1 mg/L magnesium element), the wake-up time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.1mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 0.1 mg/L magnesium), sample group 6 (containing 0.1 mg/L lithium + 200 mg/L L calcium element + 0.1 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（0.1mg/L鋰元素）單獨攝入相比，樣品組4（含0.1mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+0.1 mg/L鎂元素）、樣品組6（含0.1mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.1mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.1mg/L鋰元素與200 mg/L鈣元素或0.1 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例7  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (0.1 mg/L lithium element) alone, sample group 4 (containing 0.1 mg/L lithium element + 200 mg/L calcium element), sample group 5 (containing 0.1 mg/L lithium element + 0.1 mg/L magnesium), sample group 6 (containing 0.1 mg/L lithium + 200 mg/L calcium + 0.1 mg/L magnesium) combined intake has a more significant effect on improving sleep, and sample group 4 , There was no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.1 mg/L lithium has the effect of improving sleep; the combined use of 0.1 mg/L lithium and 200 mg/L calcium or 0.1 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 7 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表14所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表14  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 200 0 9.5 1.5 100 樣品組3 0 0.6 0 0.1 9.5 1.5 100 樣品組4 0.5 0.6 200 0 9.5 1.5 100 樣品組5 0.5 0.6 0 0.1 9.5 1.5 100 樣品組6 0.5 0.6 200 0.1 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. Table 14 shows the concentrations of minerals in drinking water for gavage in the 6 groups of sample groups, and animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 14 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 200 0 9.5 1.5 100 Sample set 3 0 0.6 0 0.1 9.5 1.5 100 Sample set 4 0.5 0.6 200 0 9.5 1.5 100 Sample set 5 0.5 0.6 0 0.1 9.5 1.5 100 Sample set 6 0.5 0.6 200 0.1 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表15所示。 表15 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% 樣品組2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% 樣品組3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% 樣品組4 261.56±12.87** 36.33%±1.79%** 417.72±14.09** 58.02%±1.96%** 40.72±3.12 5.66%±0.43% 樣品組5 263.75±11.66** 36.63%±1.62%** 413.67±13.96** 57.45%±1.94%** 42.6±3.01 5.92%±0.42% 樣品組6 262.28±11.85** 36.43%±1.65%** 415.46±13.98** 57.70%±1.94%** 42.26±2.55 5.87%±0.35% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 15. Table 15 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% Sample set 2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% Sample set 3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% Sample set 4 261.56±12.87** 36.33%±1.79%** 417.72±14.09** 58.02%±1.96%** 40.72±3.12 5.66%±0.43% Sample set 5 263.75±11.66** 36.63%±1.62%** 413.67±13.96** 57.45%±1.94%** 42.6±3.01 5.92%±0.42% Sample set 6 262.28±11.85** 36.43%±1.65%** 415.46±13.98** 57.70%±1.94%** 42.26±2.55 5.87%±0.35% Note: * means p<0.05, ** means p<0.01.

藉由表14、表15結果分析可知，與對照組相比，樣品組2（含200mg/L鈣元素）、樣品組3（含0.1 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 14 and Table 15, it can be seen that, compared with the control group, the awakening time and cumulative sleep time of the animals in sample group 2 (containing 200 mg/L calcium) and sample group 3 (containing 0.1 mg/L magnesium) were compared with the control group. There was no significant difference between the groups, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after ingesting mineral drinking water for 30 days. Sample group 1 (containing 0.5 mg/L lithium) and sample group 4 (containing 0.5 mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 0.1 mg/L magnesium) element) and sample group 6 (containing 0.5 mg/L lithium element + 200 mg/L calcium element + 0.1 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.5mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 0.1 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 200 mg/L L calcium element + 0.1 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與0.5mg/L鋰元素單獨攝入相比，樣品組4（含0.5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.5mg/L鋰元素與200 mg/L鈣元素或0.1 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例8  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of 0.5mg/L lithium element alone, sample group 4 (containing 0.5mg/L lithium element + 200 mg/L calcium element), sample group 5 (containing 0.5 mg/L lithium element + 0.1 mg/L magnesium element) element) and sample group 6 (containing 0.5mg/L lithium element + 200 mg/L calcium element + 0.1 mg/L magnesium element) combined intake has a more significant effect on improving sleep, and sample group 4, sample group 5 and There was no significant difference between sample group 6. It can be shown that drinking water containing 0.5mg/L lithium has the effect of improving sleep; the combined use of 0.5mg/L lithium and 200 mg/L calcium or 0.1 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 8 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表16所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表16  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 200 0 9.5 1.5 100 樣品組3 0 0.6 0 0.1 9.5 1.5 100 樣品組4 5 0.6 200 0 9.5 1.5 100 樣品組5 5 0.6 0 0.1 9.5 1.5 100 樣品組6 5 0.6 200 0.1 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. Table 16 shows the concentrations of minerals in drinking water for gavage in the 6 groups of sample groups. Animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 16 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 200 0 9.5 1.5 100 Sample set 3 0 0.6 0 0.1 9.5 1.5 100 Sample set 4 5 0.6 200 0 9.5 1.5 100 Sample set 5 5 0.6 0 0.1 9.5 1.5 100 Sample set 6 5 0.6 200 0.1 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表17所示。 表17 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% 樣品組2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% 樣品組3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% 樣品組4 250.63±11.45** 34.81%±1.59%** 426.89±17.02** 59.29%±2.36%** 42.48±3.03 5.90%±0.42% 樣品組5 250.76±10.78** 34.83%±1.50%** 427.56±16.32** 59.38%±2.27%** 41.68±3.21 5.79%±0.45% 樣品組6 251.23±10.45** 34.89%±1.45%** 425.43±16.67** 59.09%±2.32%** 43.34±3.08 6.02%±0.43% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed, and the statistical time period was from 6:00 to 18:00 every day. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 17. Table 17 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% Sample set 2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% Sample set 3 327.76±13.28 45.52%±1.84% 350.65±13.56 48.70%±1.88% 41.59±2.75 5.78%±0.38% Sample set 4 250.63±11.45** 34.81%±1.59%** 426.89±17.02** 59.29%±2.36%** 42.48±3.03 5.90%±0.42% Sample set 5 250.76±10.78** 34.83%±1.50%** 427.56±16.32** 59.38%±2.27%** 41.68±3.21 5.79%±0.45% Sample set 6 251.23±10.45** 34.89%±1.45%** 425.43±16.67** 59.09%±2.32%** 43.34±3.08 6.02%±0.43% Note: * means p<0.05, ** means p<0.01.

藉由表16、表17結果分析可知，與對照組相比，樣品組2（含100mg/L鈣元素）、樣品組3（含0.1 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 16 and Table 17, it can be seen that, compared with the control group, the awakening time and cumulative sleep time of the animals in sample group 2 (containing 100 mg/L calcium) and sample group 3 (containing 0.1 mg/L magnesium) were compared with the control group. There was no significant difference between the groups, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after ingesting mineral drinking water for 30 days. Sample group 1 (containing 5 mg/L lithium) and sample group 4 (containing 5 mg/L lithium + 200 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 0.1 mg/L magnesium) and In sample group 6 (containing 5 mg/L lithium element + 200 mg/L calcium element + 0.1 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), the cumulative sleep time was significantly prolonged (p < 0.01), and the sleep phase was significantly shorter (p < 0.01). The percentage of Wake was significantly decreased (p < 0.01), and the percentage of NREM during sleep was significantly increased (p < 0.01). +200 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 0.1 mg/L magnesium) and sample group 6 (containing 5 mg/L lithium + 200 mg/L calcium + 0.1 mg/L Magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含5mg/L鋰元素）單獨攝入相比，樣品組4（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+0.1 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+200 mg/L鈣元素+0.1 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中5mg/L鋰元素與200 mg/L鈣元素或0.1 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例9  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 5mg/L lithium element) alone, sample group 4 (containing 5mg/L lithium element + 200 mg/L calcium element), sample group 5 (containing 5 mg/L lithium element + 0.1 mg /L magnesium) and sample group 6 (containing 5mg/L lithium + 200 mg/L calcium + 0.1 mg/L magnesium) combined intake has a more significant effect on improving sleep, and sample group 4, sample group There was no significant difference between 5 and sample group 6. It can be shown that drinking water containing 5mg/L lithium has the effect of improving sleep; the combined use of 5mg/L lithium and 200 mg/L calcium or 0.1 mg/L magnesium in drinking water has a synergistic effect on improving sleep effect. Test Example 9 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表18所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表18  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.1 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 0.1 0 9.5 1.5 100 樣品組3 0 0.6 0 100 9.5 1.5 100 樣品組4 0.1 0.6 0.1 0 9.5 1.5 100 樣品組5 0.1 0.6 0 100 9.5 1.5 100 樣品組6 0.1 0.6 0.1 100 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 groups of sample groups are shown in Table 18, and the animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 18 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.1 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 0.1 0 9.5 1.5 100 Sample set 3 0 0.6 0 100 9.5 1.5 100 Sample set 4 0.1 0.6 0.1 0 9.5 1.5 100 Sample set 5 0.1 0.6 0 100 9.5 1.5 100 Sample set 6 0.1 0.6 0.1 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表19所示。 表19  動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% 樣品組2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% 樣品組3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% 樣品組4 267.55±11.22** 37.16%±1.56%** 412.43±14.32** 57.28%±1.99%** 40.02±2.87 5.56%±0.40% 樣品組5 268.03±10.99** 37.23%±1.53%** 410.64±15.09** 57.03%±2.10%** 41.33±3.13 5.74%±0.43% 樣品組6 268.56±10.07** 37.30%±1.40%** 411.29±14.88** 57.12%±2.07%** 40.15±3.22 5.58%±0.45% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 19. Table 19 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% Sample set 2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% Sample set 3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% Sample set 4 267.55±11.22** 37.16%±1.56%** 412.43±14.32** 57.28%±1.99%** 40.02±2.87 5.56%±0.40% Sample set 5 268.03±10.99** 37.23%±1.53%** 410.64±15.09** 57.03%±2.10%** 41.33±3.13 5.74%±0.43% Sample set 6 268.56±10.07** 37.30%±1.40%** 411.29±14.88** 57.12%±2.07%** 40.15±3.22 5.58%±0.45% Note: * means p<0.05, ** means p<0.01.

藉由表18、表19結果分析可知，與對照組相比，樣品組2（含0.1 mg/L鈣元素）、樣品組3（含100 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 18 and Table 19, it can be seen that, compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 0.1 mg/L calcium) and sample group 3 (containing 100 mg/L magnesium) were significantly different from those in the control group. Compared with the control group, there was no significant difference, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after consuming mineral drinking water for 30 days. Sample group 1 (containing 0.1 mg/L lithium) and sample group 4 (containing 0.1 mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 100 mg/L magnesium) element) and sample group 6 (containing 0.1 mg/L lithium element + 0.1 mg/L calcium element + 100 mg/L magnesium element) the awakening time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.1mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 100 mg/L magnesium) and sample group 6 (containing 0.1 mg/L lithium + 0.1 mg/L L calcium element + 100 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（0.1mg/L鋰元素）單獨攝入相比，樣品組4（含0.1mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.1mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.1mg/L鋰元素與0.1 mg/L鈣元素或100 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例10  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (0.1 mg/L lithium element) alone, sample group 4 (containing 0.1 mg/L lithium element + 0.1 mg/L calcium element), sample group 5 (containing 0.1 mg/L lithium element + 100 mg/L magnesium) and sample group 6 (containing 0.1 mg/L lithium + 0.1 mg/L calcium + 100 mg/L magnesium) combined intake has a more significant effect on improving sleep, and sample group 4 , There was no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.1 mg/L lithium has the effect of improving sleep; the combined use of 0.1 mg/L lithium and 0.1 mg/L calcium or 100 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 10 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表20所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表20  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 0.1 0 9.5 1.5 100 樣品組3 0 0.6 0 100 9.5 1.5 100 樣品組4 0.5 0.6 0.1 0 9.5 1.5 100 樣品組5 0.5 0.6 0 100 9.5 1.5 100 樣品組6 0.5 0.6 0.1 100 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 groups of sample groups are shown in Table 20. The animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 20 Composition of main minerals in drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 0.1 0 9.5 1.5 100 Sample set 3 0 0.6 0 100 9.5 1.5 100 Sample set 4 0.5 0.6 0.1 0 9.5 1.5 100 Sample set 5 0.5 0.6 0 100 9.5 1.5 100 Sample set 6 0.5 0.6 0.1 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表21所示。 表21  動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% 樣品組2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% 樣品組3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% 樣品組4 252.12±11.07** 35.02%±1.53%** 423.98±16.86** 58.89%±2.34%** 43.90±3.12 6.10%±0.43% 樣品組5 254.23±12.98** 35.31%±1.80%** 421.09±15.06** 58.48%±2.09%** 44.68±3.05 6.21%±0.42% 樣品組6 253.26±11.09** 35.18%±1.54%** 422.25±15.59** 58.65%±2.17%** 44.49±3.26 6.18%±0.45% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed, and the statistical time period was from 6:00 to 18:00 every day. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 21. Table 21 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% Sample set 2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% Sample set 3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% Sample set 4 252.12±11.07** 35.02%±1.53%** 423.98±16.86** 58.89%±2.34%** 43.90±3.12 6.10%±0.43% Sample set 5 254.23±12.98** 35.31%±1.80%** 421.09±15.06** 58.48%±2.09%** 44.68±3.05 6.21%±0.42% Sample set 6 253.26±11.09** 35.18%±1.54%** 422.25±15.59** 58.65%±2.17%** 44.49±3.26 6.18%±0.45% Note: * means p<0.05, ** means p<0.01.

藉由表20、表21結果分析可知，與對照組相比，樣品組2（含0.1 mg/L鈣元素）、樣品組3（含100 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。According to the analysis of the results in Table 20 and Table 21, compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 0.1 mg/L calcium) and sample group 3 (containing 100 mg/L magnesium) were significantly different from those in the control group. Compared with the control group, there was no significant difference, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after consuming mineral drinking water for 30 days. Sample group 1 (containing 0.5 mg/L lithium) and sample group 4 (containing 0.5 mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 100 mg/L magnesium) element) and sample group 6 (containing 0.5 mg/L lithium element + 0.1 mg/L calcium element + 100 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.5mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 100 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 0.1 mg/L L calcium element + 100 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含0.5mg/L鋰元素）單獨攝入相比，樣品組4（含0.5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.5mg/L鋰元素與0.1 mg/L鈣元素或100 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例11  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 0.5mg/L lithium element) alone, sample group 4 (containing 0.5 mg/L lithium element + 0.1 mg/L calcium element), sample group 5 (containing 0.5 mg/L lithium element) +100 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 0.1 mg/L calcium + 100 mg/L magnesium) combined intake has a more significant effect on improving sleep, and the sample group 4. There is no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.5mg/L lithium has the effect of improving sleep; the combined use of 0.5mg/L lithium and 0.1 mg/L calcium or 100 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 11 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表22所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表22  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 0.1 0 9.5 1.5 100 樣品組3 0 0.6 0 100 9.5 1.5 100 樣品組4 5 0.6 0.1 0 9.5 1.5 100 樣品組5 5 0.6 0 100 9.5 1.5 100 樣品組6 5 0.6 0.1 100 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 groups of sample groups are shown in Table 22, and the animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 22 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 0.1 0 9.5 1.5 100 Sample set 3 0 0.6 0 100 9.5 1.5 100 Sample set 4 5 0.6 0.1 0 9.5 1.5 100 Sample set 5 5 0.6 0 100 9.5 1.5 100 Sample set 6 5 0.6 0.1 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表23所示。 表23  動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% 樣品組2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% 樣品組3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% 樣品組4 250.76±11.08** 34.81%±1.54%** 429.06±16.54** 59.59%±2.30%** 40.18±3.97 5.58%±0.55% 樣品組5 253.02±11.76** 35.14%±1.63%** 426.87±15.97** 59.29%±2.22%** 40.11±4.01 5.57%±0.56% 樣品組6 251.80±10.78** 34.97%±1.50%** 428.85±15.82** 59.56%±2.20%** 39.35±4.06 5.47%±0.56% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 23. Table 23 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% Sample set 2 319.25±13.66 44.34%±1.90% 356.42±14.45 49.50%±2.01% 44.33±2.53 6.16%±0.35% Sample set 3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% Sample set 4 250.76±11.08** 34.81%±1.54%** 429.06±16.54** 59.59%±2.30%** 40.18±3.97 5.58%±0.55% Sample set 5 253.02±11.76** 35.14%±1.63%** 426.87±15.97** 59.29%±2.22%** 40.11±4.01 5.57%±0.56% Sample set 6 251.80±10.78** 34.97%±1.50%** 428.85±15.82** 59.56%±2.20%** 39.35±4.06 5.47%±0.56% Note: * means p<0.05, ** means p<0.01.

藉由表22、表23結果分析可知，與對照組相比，樣品組2（含0.1 mg/L鈣元素）、樣品組3（含100 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 22 and Table 23, it can be seen that compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 0.1 mg/L calcium) and sample group 3 (containing 100 mg/L magnesium) were significantly different from those in the control group. Compared with the control group, there was no significant difference, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after consuming mineral drinking water for 30 days. Sample group 1 (containing 5 mg/L lithium) and sample group 4 (containing 5 mg/L lithium + 0.1 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 100 mg/L magnesium) and In sample group 6 (containing 5 mg/L lithium element + 0.1 mg/L calcium element + 100 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), the cumulative sleep time was significantly prolonged (p < 0.01), and the sleep phase was significantly shorter (p < 0.01). The percentage of Wake was significantly decreased (p < 0.01), and the percentage of NREM during sleep was significantly increased (p < 0.01). +0.1 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 100 mg/L magnesium) and sample group 6 (containing 5 mg/L lithium + 0.1 mg/L calcium + 100 mg/L Magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含5mg/L鋰元素）單獨攝入相比，樣品組4（含5mg/L鋰元素+0.1 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+0.1 mg/L鈣元素+100 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中5mg/L鋰元素與0.1 mg/L鈣元素或100 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例12  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 5mg/L lithium element) alone, sample group 4 (containing 5mg/L lithium element + 0.1 mg/L calcium element), sample group 5 (containing 5mg/L lithium element + 100 mg /L magnesium) and sample group 6 (containing 5mg/L lithium + 0.1 mg/L calcium + 100 mg/L magnesium) combined intake has a more significant effect on improving sleep, and sample group 4, sample group There was no significant difference between 5 and sample group 6. It can be shown that drinking water containing 5mg/L lithium has the effect of improving sleep; the combined use of 5mg/L lithium and 0.1 mg/L calcium or 100 mg/L magnesium in drinking water has a synergistic effect on improving sleep effect. Test Example 12 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表24所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表24  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.1 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 200 0 9.5 1.5 100 樣品組3 0 0.6 0 100 9.5 1.5 100 樣品組4 0.1 0.6 200 0 9.5 1.5 100 樣品組5 0.1 0.6 0 100 9.5 1.5 100 樣品組6 0.1 0.6 200 100 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 sample groups are shown in Table 24, and the animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 24 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.1 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 200 0 9.5 1.5 100 Sample set 3 0 0.6 0 100 9.5 1.5 100 Sample set 4 0.1 0.6 200 0 9.5 1.5 100 Sample set 5 0.1 0.6 0 100 9.5 1.5 100 Sample set 6 0.1 0.6 200 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表25所示。 表25 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% 樣品組2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% 樣品組3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% 樣品組4 270.11±12.09** 37.52%±1.68%** 406.96±15.05** 56.52%±2.09%** 42.93±3.21 5.96%±0.45% 樣品組5 269.82±10.65** 37.48%±1.48%** 407.56±14.98** 56.61%±2.08%** 42.62±3.34 5.92%±0.46% 樣品組6 269.87±11.65** 37.48%±1.62%** 407.27±14.05** 56.57%±1.95%** 42.86±3.43 5.95%±0.48% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 25. Table 25 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 280.53±7.65** 38.96%±1.06%** 399.12±11.28** 55.43%±1.57** 40.35±3.08 5.60%±0.43% Sample set 2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% Sample set 3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% Sample set 4 270.11±12.09** 37.52%±1.68%** 406.96±15.05** 56.52%±2.09%** 42.93±3.21 5.96%±0.45% Sample set 5 269.82±10.65** 37.48%±1.48%** 407.56±14.98** 56.61%±2.08%** 42.62±3.34 5.92%±0.46% Sample set 6 269.87±11.65** 37.48%±1.62%** 407.27±14.05** 56.57%±1.95%** 42.86±3.43 5.95%±0.48% Note: * means p<0.05, ** means p<0.01.

藉由表24、表25結果分析可知，與對照組相比，樣品組2（含200mg/L鈣元素）、樣品組3（含100 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.1mg/L鋰元素）與樣品組4（含0.1mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 24 and Table 25, it can be seen that compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 200 mg/L calcium) and sample group 3 (containing 100 mg/L magnesium) were compared with the control group. There was no significant difference between the groups, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after ingesting mineral drinking water for 30 days. Sample group 1 (containing 0.1 mg/L lithium) and sample group 4 (containing 0.1 mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 100 mg/L magnesium) element) and sample group 6 (containing 0.1 mg/L lithium element + 200 mg/L calcium element + 100 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.1mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.1 mg/L lithium + 100 mg/L magnesium) and sample group 6 (containing 0.1 mg/L lithium + 200 mg/L L calcium element + 100 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含0.1mg/L鋰元素）單獨攝入相比，樣品組4（含0.1mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.1mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.1mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.1mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.1mg/L鋰元素與200 mg/L鈣元素或100 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例13  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 0.1 mg/L lithium element) alone, sample group 4 (containing 0.1 mg/L lithium element + 200 mg/L calcium element), sample group 5 (containing 0.1 mg/L lithium element) +100 mg/L magnesium) and sample group 6 (containing 0.1 mg/L lithium + 200 mg/L calcium + 100 mg/L magnesium) combined intake has a more significant effect on improving sleep, and the sample group 4. There is no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.1mg/L lithium has the effect of improving sleep; the combined use of 0.1mg/L lithium and 200 mg/L calcium or 100 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 13 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表26所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表26  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 0.5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 200 0 9.5 1.5 100 樣品組3 0 0.6 0 100 9.5 1.5 100 樣品組4 0.5 0.6 200 0 9.5 1.5 100 樣品組5 0.5 0.6 0 100 9.5 1.5 100 樣品組6 0.5 0.6 200 100 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. The concentrations of minerals in drinking water for gavage in the 6 groups of sample groups are shown in Table 26, and the animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 26 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 0.5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 200 0 9.5 1.5 100 Sample set 3 0 0.6 0 100 9.5 1.5 100 Sample set 4 0.5 0.6 200 0 9.5 1.5 100 Sample set 5 0.5 0.6 0 100 9.5 1.5 100 Sample set 6 0.5 0.6 200 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表27所示。 表27 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% 樣品組2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% 樣品組3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% 樣品組4 256.12±13.08** 35.57%±1.82%** 419.65±15.07** 58.28%±2.09%** 44.23±3.52 6.14%±0.49% 樣品組5 259.34±13.98** 36.02%±1.94%** 417.54±14.86** 57.99%±2.06%** 43.12±3.24 5.99%±0.45% 樣品組6 257.37±12.45** 35.75%±1.73%** 418.44±14.92** 58.12%±2.07%** 44.19±3.67 6.14%±0.51% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 27. Table 27 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 270.53±8.45** 37.57%±1.17%** 406.16±12.58** 56.41%±1.75** 43.31±3.15 6.02%±0.44% Sample set 2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% Sample set 3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% Sample set 4 256.12±13.08** 35.57%±1.82%** 419.65±15.07** 58.28%±2.09%** 44.23±3.52 6.14%±0.49% Sample set 5 259.34±13.98** 36.02%±1.94%** 417.54±14.86** 57.99%±2.06%** 43.12±3.24 5.99%±0.45% Sample set 6 257.37±12.45** 35.75%±1.73%** 418.44±14.92** 58.12%±2.07%** 44.19±3.67 6.14%±0.51% Note: * means p<0.05, ** means p<0.01.

藉由表26、表27結果分析可知，與對照組相比，樣品組2（含200mg/L鈣元素）、樣品組3（含100 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含0.5mg/L鋰元素）與樣品組4（含0.5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。According to the analysis of the results in Table 26 and Table 27, compared with the control group, the wake-up time and cumulative sleep time of the animals in sample group 2 (containing 200 mg/L calcium) and sample group 3 (containing 100 mg/L magnesium) were compared with the control group. There was no significant difference between the groups, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after ingesting mineral drinking water for 30 days. Sample group 1 (containing 0.5 mg/L lithium) and sample group 4 (containing 0.5 mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 100 mg/L magnesium) element) and sample group 6 (containing 0.5 mg/L lithium element + 200 mg/L calcium element + 100 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01) , the percentage of Wake in the sleep phase was significantly decreased (p<0.01), and the percentage of NREM in the sleep phase was significantly increased (p<0.01). 0.5mg/L lithium + 200 mg/L calcium), sample group 5 (containing 0.5 mg/L lithium + 100 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 200 mg/L L calcium element + 100 mg/L magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含0.5mg/L鋰元素）單獨攝入相比，樣品組4（含0.5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含0.5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含0.5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有0.5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中0.5mg/L鋰元素與200 mg/L鈣元素或100 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例14  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 0.5mg/L lithium element) alone, sample group 4 (containing 0.5 mg/L lithium element + 200 mg/L calcium element), sample group 5 (containing 0.5 mg/L lithium element) +100 mg/L magnesium) and sample group 6 (containing 0.5 mg/L lithium + 200 mg/L calcium + 100 mg/L magnesium) combined intake has a more significant effect on improving sleep, and the sample group 4. There is no significant difference between sample group 5 and sample group 6. It can be shown that drinking water containing 0.5mg/L lithium has the effect of improving sleep; the combined use of 0.5mg/L lithium and 200 mg/L calcium or 100 mg/L magnesium in drinking water has a synergistic effect on improving sleep synergistic effect. Test Example 14 Animal verification test of the effect of drinking water on improving sleep

取小鼠105隻，隨機分成7組，分別為對照組和6組受試樣品組。6組樣品組灌胃用飲用水各礦物質濃度如表28所示，對照組動物給樣品組同等體積的無菌蒸餾水。每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。 表28  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 5 0.6 0 0 9.5 1.5 100 樣品組2 0 0.6 200 0 9.5 1.5 100 樣品組3 0 0.6 0 100 9.5 1.5 100 樣品組4 5 0.6 200 0 9.5 1.5 100 樣品組5 5 0.6 0 100 9.5 1.5 100 樣品組6 5 0.6 200 100 9.5 1.5 100 A total of 105 mice were randomly divided into 7 groups, namely the control group and the 6 test sample groups. Table 28 shows the concentrations of minerals in drinking water for gavage in the 6 groups of sample groups. The animals in the control group were given the same volume of sterile distilled water in the sample groups. 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. Table 28 Main mineral composition of drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 5 0.6 0 0 9.5 1.5 100 Sample set 2 0 0.6 200 0 9.5 1.5 100 Sample set 3 0 0.6 0 100 9.5 1.5 100 Sample set 4 5 0.6 200 0 9.5 1.5 100 Sample set 5 5 0.6 0 100 9.5 1.5 100 Sample set 6 5 0.6 200 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表29所示。 表29 動物睡眠實驗結果 組別 覺醒（min） Wake（%） NREM睡眠（min） NREM（%） REM睡眠（min） REM（%） 對照組 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% 樣品組1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% 樣品組2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% 樣品組3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% 樣品組4 248.63±11.02** 34.53%±1.53%** 429.89±14.86** 59.71%±2.06%** 41.48±3.04 5.76%±0.42% 樣品組5 250.33±11.21** 34.77%±1.56%** 426.96±14.33** 59.30%±1.99%** 42.71±3.24 5.93%±0.45% 樣品組6 249.68±10.45** 34.68%±1.45%** 429.40±15.02** 59.64%±2.09%** 40.92±3.98 5.68%±0.55% 注:*表示p＜0.05，**表示p＜0.01。Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 29. Table 29 Results of animal sleep experiments group Awakening (min) Wake (%) NREM sleep (min) NREM (%) REM sleep (min) REM (%) control group 323.21±11.62 44.89%±1.61% 354.19±16.55 49.19%±0.91 42.60±2.78 5.92%±0.39% Sample set 1 268.49±9.42** 37.29%±1.31%** 409.13±12.98** 56.82%±1.80** 42.38±2.99 5.89%±0.42% Sample set 2 322.63±13.06 44.81%±1.81% 352.42±13.15 48.95%±1.83% 44.95±2.59 6.16%±0.36% Sample set 3 320.79±14.95 44.55%±2.08% 355.68±13.77 49.40%±1.91% 43.53±2.59 6.05%±0.36% Sample set 4 248.63±11.02** 34.53%±1.53%** 429.89±14.86** 59.71%±2.06%** 41.48±3.04 5.76%±0.42% Sample set 5 250.33±11.21** 34.77%±1.56%** 426.96±14.33** 59.30%±1.99%** 42.71±3.24 5.93%±0.45% Sample set 6 249.68±10.45** 34.68%±1.45%** 429.40±15.02** 59.64%±2.09%** 40.92±3.98 5.68%±0.55% Note: * means p<0.05, ** means p<0.01.

藉由表28、表29結果分析可知，與對照組相比，樣品組2（含200mg/L鈣元素）、樣品組3（含100 mg/L鎂元素）動物覺醒時間與累積睡眠時間與對照組相比均無顯著性差異，睡眠時相變化不明顯，說明樣品組2與樣品組3動物攝入礦物質飲用水30天後沒有發現改善睡眠的作用。樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含5mg/L鋰元素）與樣品組4（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。From the analysis of the results in Table 28 and Table 29, it can be seen that compared with the control group, the awakening time and cumulative sleep time of the animals in sample group 2 (containing 200 mg/L calcium) and sample group 3 (containing 100 mg/L magnesium) were compared with the control group. There was no significant difference between the groups, and the sleep phase changes were not obvious, indicating that the animals of sample group 2 and sample group 3 did not find the effect of improving sleep after ingesting mineral drinking water for 30 days. Sample group 1 (containing 5 mg/L lithium) and sample group 4 (containing 5 mg/L lithium + 200 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 100 mg/L magnesium) and In sample group 6 (containing 5 mg/L lithium element + 200 mg/L calcium element + 100 mg/L magnesium element), the awakening time of animals was significantly shortened (p < 0.01), the cumulative sleep time was significantly prolonged (p < 0.01), and the sleep phase was significantly shorter (p < 0.01). The percentage of Wake was significantly decreased (p < 0.01), and the percentage of NREM during sleep was significantly increased (p < 0.01). +200 mg/L calcium), sample group 5 (containing 5 mg/L lithium + 100 mg/L magnesium) and sample group 6 (containing 5 mg/L lithium + 200 mg/L calcium + 100 mg/L Magnesium element) animals ingested the drinking water of the present invention for 30 days and the sleep situation was improved.

與樣品組1（含5mg/L鋰元素）單獨攝入相比，樣品組4（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組5（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組6（含5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）組合攝入對改善睡眠作用的效果更顯著，且樣品組4、樣品組5與樣品組6之間無顯著性差異。可以說明，含有5mg/L鋰元素的飲用水具有改善睡眠的作用；飲用水中5mg/L鋰元素與200 mg/L鈣元素或100 mg/L鎂元素的組合使用對改善睡眠具有協同增效作用。 試驗例15  飲用水改善睡眠功效的動物驗證試驗Compared with the intake of sample group 1 (containing 5mg/L lithium element) alone, sample group 4 (containing 5mg/L lithium element + 200 mg/L calcium element), sample group 5 (containing 5mg/L lithium element + 100 mg /L magnesium) and sample group 6 (containing 5mg/L lithium + 200 mg/L calcium + 100 mg/L magnesium) combined intake has a more significant effect on improving sleep, and sample group 4, sample group There was no significant difference between 5 and sample group 6. It can be shown that drinking water containing 5mg/L lithium has the effect of improving sleep; the combination of 5mg/L lithium and 200 mg/L calcium or 100 mg/L magnesium in drinking water has a synergistic effect on improving sleep effect. Test Example 15 Animal verification test of the effect of drinking water on improving sleep

睡眠環境的變化可能會施加新的生理和心理刺激，從而極大地影響人的睡眠時間和品質。將動物放置在新環境中或更換籠子時，也會發生類似現象。籠交換模型提供了一種有價值的失眠模型，其行為和電生理學與人類因壓力引起的失眠相似。取小鼠60隻，隨機分成4組，分別為對照組和受試樣品組。實驗動物從手術結束後到開始記錄約2週時間內接受標準飼養，並進行5次籠子更換。在最後一次籠子更換後記錄2日6時-18時的基準睡眠。基準睡眠記錄結束後每組15隻進行連續灌胃給飲用水樣品。每天灌胃一次，週期為30天。3組樣品組灌胃用飲用水各礦物質濃度如表30所示，對照組動物給樣品組同等體積的無菌蒸餾水。 表30  實驗用飲用水主要礦物質組成 礦物質濃度mg/L 鋰 鍶 鈣 鎂 偏矽酸 鉀 鈉 對照組 0 0 0 0 0 0 0 樣品組1 5 0.6 200 0 9.5 1.5 100 樣品組2 5 0.6 0 100 9.5 1.5 100 樣品組3 5 0.6 200 100 9.5 1.5 100 Changes in the sleep environment may impose new physiological and psychological stimuli that greatly affect the duration and quality of a person's sleep. A similar phenomenon occurs when animals are placed in new environments or when cages are changed. The cage exchange model provides a valuable model of insomnia that behaves and electrophysiologically resembles stress-induced insomnia in humans. A total of 60 mice were randomly divided into 4 groups, namely the control group and the test sample group. The experimental animals received standard feeding and 5 cage changes from the end of the operation to the start of recording for about 2 weeks. Baseline sleep at 6:00-18:00 on the 2nd was recorded after the last cage change. After the baseline sleep recording, 15 rats in each group were continuously gavaged with drinking water samples. Gavage once a day for a period of 30 days. The concentration of each mineral in the drinking water for gavage in the three sample groups is shown in Table 30, and the animals in the control group were given the same volume of sterile distilled water in the sample group. Table 30 Composition of main minerals in drinking water for experiment Mineral concentration mg/L lithium strontium calcium magnesium metasilicic acid Potassium sodium control group 0 0 0 0 0 0 0 Sample set 1 5 0.6 200 0 9.5 1.5 100 Sample set 2 5 0.6 0 100 9.5 1.5 100 Sample set 3 5 0.6 200 100 9.5 1.5 100

給藥結束後連續三天對動物進行多導睡眠圖記錄。對動物皮層腦電圖與肌電圖進行分析，統計時間段為每日6時-18時，以三日平均覺醒時間、睡眠時間以及各睡眠時相所占百分比（Wake%、NREM%、REM%）為觀察指標，研究小鼠睡眠時間和睡眠時相的變化情況。實驗結果如表31所示。 表31 籠交換動物模型睡眠實驗結果 組別 覺醒（min） Wake（%） NREM（min） NREM（%） REM（min） REM（%） 對照組 410.67±18.14 57.04%±2.52% 274.22±13.65 38.09%±1.90% 35.11±3.09 4.88%±0.43% 樣品組1 292.21±10.99** 40.58%±1.53%** 384.53±15.62** 53.41%±2.17%** 43.26±3.65 6.01%±0.5% 樣品組2 293.64±11.97** 40.78%±1.66%** 383.91±14.67** 53.32%±2.04%** 42.45±3.23 5.90%±0.45% 樣品組3 290.88±11.56** 40.4%±1.61%** 386.14±15.73** 53.63%±2.18%** 42.98±3.21** 5.97%±0.45%** Animals were subjected to polysomnography recordings for three consecutive days after the end of dosing. The animal cortical EEG and EMG were analyzed. The statistical time period was from 6:00 to 18:00 every day, and the average awakening time, sleep time and the percentage of each sleep phase (Wake%, NREM%, REM) were used for three days. %) as the observation index, to study the changes of the sleep time and sleep phase of the mice. The experimental results are shown in Table 31. Table 31 Results of sleep experiments in cage exchange animal models group Awakening (min) Wake (%) NREM (min) NREM (%) REM (min) REM (%) control group 410.67±18.14 57.04%±2.52% 274.22±13.65 38.09%±1.90% 35.11±3.09 4.88%±0.43% Sample set 1 292.21±10.99** 40.58%±1.53%** 384.53±15.62** 53.41%±2.17%** 43.26±3.65 6.01%±0.5% Sample set 2 293.64±11.97** 40.78%±1.66%** 383.91±14.67** 53.32%±2.04%** 42.45±3.23 5.90%±0.45% Sample set 3 290.88±11.56** 40.4%±1.61%** 386.14±15.73** 53.63%±2.18%** 42.98±3.21** 5.97%±0.45%**

藉由表30、表31結果分析可知，與對照組相比，樣品組1（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組2（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組3（含5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物覺醒時間明顯縮短（p＜0.01），累積睡眠時間明顯延長（p＜0.01），睡眠時相Wake所占百分比明顯減少（p＜0.01），睡眠時相NREM所占百分比明顯增多（p＜0.01）；說明樣品組1（含5mg/L鋰元素+200 mg/L鈣元素）、樣品組2（含5mg/L鋰元素+100 mg/L鎂元素）及樣品組3（含5mg/L鋰元素+200 mg/L鈣元素+100 mg/L鎂元素）動物攝入本發明飲用水30天後睡眠情況得到改善。該結果可以提示，針對因睡眠環境變化引發生理和心理刺激造成難以入睡情況的失眠人群，一定程度上可以改善睡眠品質。According to the analysis of the results in Table 30 and Table 31, compared with the control group, sample group 1 (containing 5 mg/L lithium element + 200 mg/L calcium element), sample group 2 (containing 5 mg/L lithium element + 100 mg/L element L magnesium element) and sample group 3 (containing 5 mg/L lithium element + 200 mg/L calcium element + 100 mg/L magnesium element) the wake-up time of animals was significantly shortened (p < 0.01), and the cumulative sleep time was significantly prolonged (p < 0.01). ), the percentage of Wake in the sleep phase was significantly decreased (p < 0.01), and the percentage of NREM in the sleep phase was significantly increased (p < 0.01). ), sample group 2 (containing 5mg/L lithium element + 100 mg/L magnesium element) and sample group 3 (containing 5mg/L lithium element + 200 mg/L calcium element + 100 mg/L magnesium element) animal intake of this Sleep was improved after 30 days of drinking water. The results suggest that sleep quality can be improved to a certain extent for insomniacs who have difficulty falling asleep due to physiological and psychological stimuli caused by changes in the sleeping environment.

綜合以上試驗例，可以說明含有0.1~5mg/L鋰元素的飲用水具有改善睡眠的作用；同時含有0.1~5mg/L鋰元素與0.1~200mg/L鈣元素，或同時含有0.1~5mg/L鋰元素與0.1~100mg/L鎂元素的飲用水對改善睡眠具有協同增效的作用。並且，針對因睡眠環境變化引發生理和心理刺激造成難以入睡情況的失眠人群，攝入本發明飲用水一定程度上可以改善睡眠品質。成年人每天飲用24mL或以上的本發明飲用水，可以達到改善睡眠的效果（起效量是依據小鼠與人之間的換算公式（動物實驗飲用水樣品的鋰濃度×灌胃給藥體積0.5mL×（人平均體重60kg/小鼠體重25g）/10/實際飲用水的鋰濃度）得到的（其中，動物實驗飲用水樣品的鋰濃度和實際飲用水的鋰濃度均為0.1~5mg/L之間的某值，例如動物實驗飲用水樣品的鋰濃度為0.1mg/L，實際飲用水的鋰濃度為0.5mg/L））。Based on the above test examples, it can be shown that drinking water containing 0.1~5mg/L lithium element has the effect of improving sleep; at the same time containing 0.1~5mg/L lithium element and 0.1~200mg/L calcium element, or containing 0.1~5mg/L at the same time Lithium and 0.1-100mg/L magnesium in drinking water have a synergistic effect on improving sleep. In addition, for insomniacs who are difficult to fall asleep due to physiological and psychological stimulation caused by changes in the sleeping environment, ingesting the drinking water of the present invention can improve sleep quality to a certain extent. Adults drink 24mL or more of the drinking water of the present invention every day to achieve the effect of improving sleep (the effective dose is based on the conversion formula between mice and humans (lithium concentration of drinking water samples in animal experiments × gavage volume 0.5 mL×(average human body weight 60kg/mouse body weight 25g)/10/lithium concentration in actual drinking water) (wherein, the lithium concentration of the drinking water samples of animal experiments and the lithium concentration of actual drinking water are both 0.1~5mg/L A certain value between, for example, the lithium concentration of drinking water samples in animal experiments is 0.1 mg/L, and the lithium concentration of actual drinking water is 0.5 mg/L)).

以上所述僅為本發明的較佳實施例而已，並不用以限制本發明，凡在本發明的精神和原則之內，所作的任何修改、等同替換、改進等，均應包含在本發明的保護範圍之內。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of the present invention. within the scope of protection.

Claims (40)

一種飲用水用於改善睡眠品質或緩解睡眠障礙的用途，該飲用水含有0.1~5mg/L鋰和0.1~200mg/L鈣，或含有0.1~5mg/L鋰和0.1~100mg/L鎂，該用途不用於診斷或治療目的。 Use of drinking water for improving sleep quality or relieving sleep disorders, the drinking water contains 0.1-5mg/L lithium and 0.1-200mg/L calcium, or 0.1-5mg/L lithium and 0.1-100mg/L magnesium, the drinking water contains 0.1-5mg/L lithium and 0.1-200mg/L calcium Use is not for diagnostic or therapeutic purposes. 如請求項1所述的用途，該飲用水中的鋰、鈣和鎂分別以Li+、Ca2+、Mg2+的形式存在。 According to the use according to claim 1, lithium, calcium and magnesium in the drinking water are respectively in the form of Li + , Ca 2+ and Mg 2+ . 如請求項1所述的用途，該飲用水中的鋰含量為0.1~0.2mg/L、0.2~0.5mg/L、0.5~1mg/L、1~2mg/L、2~3mg/L、3~4mg/L或4~5mg/L。 According to the use described in claim 1, the lithium content in the drinking water is 0.1~0.2mg/L, 0.2~0.5mg/L, 0.5~1mg/L, 1~2mg/L, 2~3mg/L, 3 ~4mg/L or 4~5mg/L. 如請求項1所述的用途，該飲用水中的鈣含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~60mg/L、60~80mg/L、80~100mg/L、100~120mg/L、120~140mg/L、140~160mg/L、160~180mg/L或180~200mg/L。 According to the use described in claim 1, the calcium content in the drinking water is 0.1~1mg/L, 1~10mg/L, 10~20mg/L, 20~40mg/L, 40~60mg/L, 60~80mg /L, 80~100mg/L, 100~120mg/L, 120~140mg/L, 140~160mg/L, 160~180mg/L or 180~200mg/L. 如請求項1所述的用途，該飲用水中的鎂含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~50mg/L、50~60mg/L、60~80mg/L或80~100mg/L。 According to the use described in claim 1, the magnesium content in the drinking water is 0.1~1mg/L, 1~10mg/L, 10~20mg/L, 20~40mg/L, 40~50mg/L, 50~60mg /L, 60~80mg/L or 80~100mg/L. 如請求項1所述的用途，該飲用水還包含以下元素中的一種或多種：鍶、鉀、鈉。 According to the use described in claim 1, the drinking water further comprises one or more of the following elements: strontium, potassium and sodium. 如請求項1所述的用途，該飲用水還包含偏矽酸。 The use according to claim 1, the drinking water further comprising metasilicic acid. 如請求項1所述的用途，該飲用水還包含碳酸根和氯離子。 The use according to claim 1, the drinking water further comprising carbonate and chloride ions. 如請求項6所述的用途，該飲用水中的鍶、鉀、鈉分別以Sr2+、K+、Na+的形式存在。 According to the use according to claim 6, strontium, potassium and sodium in the drinking water exist in the form of Sr 2+ , K + and Na + respectively. 如請求項6所述的用途，該飲用水中的鍶含量為0.4~1.5mg/L。 According to the use according to claim 6, the strontium content in the drinking water is 0.4-1.5 mg/L. 如請求項6所述的用途，該飲用水中的鉀含量為0.8~3mg/L。 According to the use described in claim 6, the potassium content in the drinking water is 0.8-3 mg/L. 如請求項6所述的用途，該飲用水中的鈉含量為50~160mg/L。 According to the use described in claim 6, the sodium content in the drinking water is 50-160 mg/L. 如請求項7所述的用途，該飲用水中的偏矽酸含量為6~20mg/L。 According to the use described in claim 7, the content of metasilicic acid in the drinking water is 6-20 mg/L. 如請求項1所述的用途，該飲用水含有0.2~0.5mg/L鋰和4~20mg/L鈣，以及任選的鍶、鉀、鈉和/或偏矽酸；或者該飲用水含有0.2~0.5mg/L鋰和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。 The use according to claim 1, the drinking water contains 0.2-0.5 mg/L lithium and 4-20 mg/L calcium, and optionally strontium, potassium, sodium and/or metasilicic acid; or the drinking water contains 0.2 ~0.5mg/L lithium and 1~6mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid. 如請求項1所述的用途，該飲用水含有0.2~0.5mg/L鋰、4~20mg/L鈣和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。 The use according to claim 1, the drinking water containing 0.2-0.5 mg/L lithium, 4-20 mg/L calcium and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid . 如請求項1所述的用途，該飲用水含有0.2~0.5mg/L鋰，0.4~1.5mg/L鍶，4~20mg/L鈣，1~6mg/L鎂，6~20mg/L偏矽酸，0.8~3mg/L鉀，以及50~160mg/L鈉。 For the purpose of claim 1, the drinking water contains 0.2~0.5mg/L lithium, 0.4~1.5mg/L strontium, 4~20mg/L calcium, 1~6mg/L magnesium, 6~20mg/L metasilicon Acid, 0.8~3mg/L potassium, and 50~160mg/L sodium. 如請求項1至請求項16中任一項所述的用途，該飲用水是礦泉水或礦物質水。 The use according to any one of claim 1 to claim 16, wherein the drinking water is mineral water or mineral water. 如請求項1至請求項6中任一項所述的用途，該飲用水被包裝於容器中。 The use according to any one of claims 1 to 6, wherein the drinking water is packaged in a container. 如請求項18所述的用途，該容器為玻璃瓶、塑膠瓶、盒、罐或桶。 The use according to claim 18, the container is a glass bottle, a plastic bottle, a box, a jar or a barrel. 一種改善睡眠品質或緩解睡眠障礙的方法，該方法包括飲用如請求項1至請求項19中任一項定義的飲用水，該方法不用於診斷或治療目的。 A method of improving sleep quality or alleviating sleep disorders, the method comprising drinking drinking water as defined in any one of claim 1 to claim 19, the method not being used for diagnostic or therapeutic purposes. 如請求項20所述的方法，該方法包括每日飲用至少24mL該飲用水。 The method of claim 20, comprising drinking at least 24 mL of the drinking water per day. 一種含有鋰、鈣、鎂的一水在製備用於改善睡眠品質或緩解睡眠障礙的一食品或藥物中的用途，該水中，鋰的含量為0.1~5mg/L且鈣的含量為0.1~200mg/L，或鋰的含量為0.1~5mg/L且鎂的含量為0.1~100mg/L。 Use of a water containing lithium, calcium and magnesium in the preparation of a food or medicine for improving sleep quality or relieving sleep disorders, wherein the content of lithium in the water is 0.1-5 mg/L and the content of calcium is 0.1-200 mg /L, or the content of lithium is 0.1 to 5 mg/L and the content of magnesium is 0.1 to 100 mg/L. 如請求項22所述的用途，該食品為飲料。 The use according to claim 22, the food is a beverage. 如請求項22所述的用途，該食品為飲用水。 The use according to claim 22, the food is drinking water. 如請求項22所述的用途，該食品為礦泉水或礦物質水。 The use according to claim 22, the food is mineral water or mineral water. 如請求項22所述的用途，該水中的鋰、鈣和鎂分別以Li+、Ca2+、Mg2+的形式存在。 The use according to claim 22, wherein the lithium, calcium and magnesium in the water are respectively in the form of Li + , Ca 2+ and Mg 2+ . 如請求項22所述的用途，該水中的鋰含量為0.1~0.2mg/L、0.2~0.5mg/L、0.5~1mg/L、1~2mg/L、2~3mg/L、3~4mg/L或4~5mg/L。 The use according to claim 22, the lithium content in the water is 0.1~0.2mg/L, 0.2~0.5mg/L, 0.5~1mg/L, 1~2mg/L, 2~3mg/L, 3~4mg /L or 4~5mg/L. 如請求項22所述的用途，該水中的鈣含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~60mg/L、60~80mg/L、80~100mg/L、100~120mg/L、120~140mg/L、140~160mg/L、160~180mg/L或180~200mg/L。 The use according to claim 22, the calcium content in the water is 0.1~1mg/L, 1~10mg/L, 10~20mg/L, 20~40mg/L, 40~60mg/L, 60~80mg/L , 80~100mg/L, 100~120mg/L, 120~140mg/L, 140~160mg/L, 160~180mg/L or 180~200mg/L. 如請求項22所述的用途，該水中的鎂含量為0.1~1mg/L、1~10mg/L、10~20mg/L、20~40mg/L、40~50mg/L、50~60mg/L、60~80mg/L或80~100mg/L。 The use according to claim 22, the magnesium content in the water is 0.1~1mg/L, 1~10mg/L, 10~20mg/L, 20~40mg/L, 40~50mg/L, 50~60mg/L , 60~80mg/L or 80~100mg/L. 如請求項22所述的用途，該水還包含以下元素中的一種或多種：鍶、鉀、鈉。 The use according to claim 22, the water further comprises one or more of the following elements: strontium, potassium, and sodium. 如請求項22所述的用途，該水還包含偏矽酸。 The use according to claim 22, the water further comprising metasilicic acid. 如請求項22所述的用途，該水還包含碳酸根和氯離子。 The use according to claim 22, the water further comprising carbonate and chloride ions. 如請求項30所述的用途，該水中的鍶、鉀、鈉分別以Sr2+、K+、Na+的形式存在。 According to the use according to claim 30, the strontium, potassium and sodium in the water exist in the form of Sr 2+ , K + and Na + respectively. 如請求項30所述的用途，該水中的鍶含量為0.4~1.5mg/L。 According to the use according to claim 30, the strontium content in the water is 0.4-1.5 mg/L. 如請求項30所述的用途，該水中的鉀含量為0.8~3mg/L。 According to the use described in claim 30, the potassium content in the water is 0.8-3 mg/L. 如請求項30所述的用途，該水中的鈉含量為50~160mg/L。 According to the use described in claim 30, the sodium content in the water is 50-160 mg/L. 如請求項31所述的用途，該水中的偏矽酸含量為6~20mg/L。 According to the use according to claim 31, the content of metasilicic acid in the water is 6-20 mg/L. 如請求項22所述的用途，該水含有0.2~0.5mg/L鋰和4~20mg/L鈣，以及任選的鍶、鉀、鈉和/或偏矽酸；或者該水含有0.2~0.5mg/L鋰和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。 The use according to claim 22, wherein the water contains 0.2-0.5 mg/L lithium and 4-20 mg/L calcium, and optionally strontium, potassium, sodium and/or metasilicic acid; or the water contains 0.2-0.5 mg/L lithium and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid. 如請求項22所述的用途，該水含有0.2~0.5mg/L鋰、4~20mg/L鈣和1~6mg/L鎂，以及任選的鍶、鉀、鈉和/或偏矽酸。 The use as claimed in claim 22, wherein the water contains 0.2-0.5 mg/L lithium, 4-20 mg/L calcium and 1-6 mg/L magnesium, and optionally strontium, potassium, sodium and/or metasilicic acid. 如請求項22所述的用途，該水含有0.2~0.5mg/L鋰，0.4~1.5mg/L鍶，4~20mg/L鈣，1~6mg/L鎂，6~20mg/L偏矽酸，0.8~3mg/L鉀，以及50~160mg/L鈉。 The use according to claim 22, the water contains 0.2~0.5mg/L lithium, 0.4~1.5mg/L strontium, 4~20mg/L calcium, 1~6mg/L magnesium, 6~20mg/L metasilicic acid , 0.8~3mg/L potassium, and 50~160mg/L sodium.
TW110114227A 2020-05-11 2021-04-21 A drinking water that improves sleep quality TWI760194B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010390636.7A CN111453831A (en) 2020-05-11 2020-05-11 Drinking water for improving sleep quality
CN202010390636.7 2020-05-11

Publications (2)

Publication Number Publication Date
TW202142123A TW202142123A (en) 2021-11-16
TWI760194B true TWI760194B (en) 2022-04-01

Family

ID=71674718

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110114227A TWI760194B (en) 2020-05-11 2021-04-21 A drinking water that improves sleep quality

Country Status (3)

Country Link
CN (1) CN111453831A (en)
TW (1) TWI760194B (en)
WO (1) WO2021227796A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111453831A (en) * 2020-05-11 2020-07-28 浙江养生堂天然药物研究所有限公司 Drinking water for improving sleep quality

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107654C (en) * 1998-02-17 2003-05-07 北京屈臣氏蒸馏水有限公司 Mineral water and production thereof
CN101049150B (en) * 2006-07-25 2010-09-15 陈治先 Edible nourishment health care potassium salt with extensive use
WO2008127524A2 (en) * 2007-03-07 2008-10-23 The Regents Of The University Of Californina Biomarkers of very rapid antidepressant response and of mechanism of very rapid antidepressant response
CN101416764A (en) * 2007-10-26 2009-04-29 周博 A kind of multi-element mineral water and preparation method thereof
CN101318733A (en) * 2008-01-21 2008-12-10 付全贵 Water purifying mineral spring machine for preventing cardiovascular disease
CN104509923A (en) * 2013-12-26 2015-04-15 容宁 Weakly alkaline drinking water
KR20160052935A (en) * 2014-10-29 2016-05-13 주식회사 아리바이오 Compositions for preventing or improving decrease in blood pressure or related symptoms comprising mineral water with high hardness prepared using saline groundwater or deep sea water
CN106036877A (en) * 2016-06-29 2016-10-26 中国人民解放军第三军医大学第附属医院 Nutritional compound for improving sleep and application thereof
CN110050929A (en) * 2018-01-19 2019-07-26 辽宁科硕营养科技股份有限公司 A kind of drinks with replenish the calcium, improve sleep and angst resistance effect
CN111453831A (en) * 2020-05-11 2020-07-28 浙江养生堂天然药物研究所有限公司 Drinking water for improving sleep quality

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
期刊韕ABDULLAHI Arabi Suleiman , 韕 韕"Assessment of Calcium and Magnesium Concentrations in Groundwater as Supplements for Sleep Related Ailments", 韕 3(7), 韕J. Appl. Environ. Biol. Sci.,韕2013, 韕29-35.韕; *
期刊韕Rita Masciale et al., 韕 韕"Impact of a very low enthalpy plant on a costal aquifer: a case study in Southern Italy", 韕3,韕Environ Earth Sci,韕 2015韕.韕; *
期刊韕Simone M. Ota et al.,韕 韕 "Lithium Prevents REM Sleep Deprivation-Induced Impairments on Memory Consolidation",韕Vol. 36, No. 11, 韕 SLEEP, 韕2013,韕1677-1684.韕; *
期刊韕ZENG Ying et al., 韕 韕"Prediction Of Water Quality Of Bicarbonate Mineral Water In WUDALIANCHI Based on BP Neural Network Model", 韕53,韕E3S Web of Conferences ,韕 2018韕.韕 *

Also Published As

Publication number Publication date
TW202142123A (en) 2021-11-16
WO2021227796A1 (en) 2021-11-18
CN111453831A (en) 2020-07-28

Similar Documents

Publication Publication Date Title
Blass et al. Suckling-and sucrose-induced analgesia in human newborns
KR20070085838A (en) Method for treatment of movement disorders
CH701268B1 (en) Homeopathic formulation.
JP2007084515A (en) Medicine for ameliorating anorexia of patient in low nutritional state
TWI760194B (en) A drinking water that improves sleep quality
EP3909576A1 (en) Use of chlorogenic acid in preparing medicine or pharmaceutical composition for preventing or treating pain
DE69031694T3 (en) Glutamine for the treatment of impaired immunity
EP3031455B1 (en) Agent for the treatment and prevention of sleep disorders
CN107320674A (en) A kind of Chinese medicine composition and its application
Valle et al. Auricular Hematoma in a Dog Treated by Homeopathic Therapy-Case Report
CN112546120B (en) Product containing folic acid for relieving anxiety
Sandstead Clinical manifestations of certain classical deficiency diseases
CN114522183A (en) Sea cucumber extract for increasing bone mineral density
Blackwood et al. Materia Medica
CN115531365B (en) Application of chlorogenic acid composition in preparation of medicines for preventing or treating pain
WO2022239714A1 (en) Agent for preventing or improving nocturia, wakefulness after sleep onset, or frequent urination
Shreeve Alternative Dictionary Of Symptoms And Cures: A Comprehensive Guide to Diseases and Their Orthodox and Alternative Remedies
CN109289002B (en) Medicinal and edible composition
CN108785649B (en) Composition for controlling weight of pressure type obesity
Glaser Visceral manifestations of epilepsy
Ziering Immediate and late side effects of hay fever: Physical and psychosocial problems
Rahlin Neurological and Neuromuscular Systems Medical and Surgical Management of Alterations in Body Structures and Functions
Wilson Useful prescriptions
Schilling Parkinson’s Disease May Be Stopped
CN118078936A (en) Application of sixteen-ingredient azalea pill in preventing and treating neuralgia